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ABSTRACT
An Epidemiological Assessment of Lung Function Decline as a
Predictor of Morbidity and Mortality
Penelope J. Baughman
Excessive lung function decline is associated with increased risks of respiratory morbidity and
mortality outcomes including chronic obstructive pulmonary disease (COPD). COPD is a disease
afflicting approximately 80 million people worldwide and as of 2002, the fifth leading cause of
death. COPD is an increasing problem, with substantial increases projected in COPD deaths if
there is no reduction of the causal risk factors. By 2030, COPD is projected to be the third
leading cause of death worldwide, an increase mainly due to extended life expectancies and that
COPD deaths occur at older ages. COPD is also largely underdiagnosed, partially due to the
gradual development of the disease, and is a very costly illness that reduces labor force
participation in its more severe stages. Existing studies of lung function decline as a predictor of
morbidity and mortality are focused upon assessing lung function decline as an independent risk
factor among other known risk factors. The objective of this study was to assess lung function as
a predictor of morbidity and mortality in minimally-adjusted models to provide information for
prevention purposes of both lung function decline and associated morbidity and mortality
outcomes. The population-based Copenhagen City Heart Study data (1976–2003) were used to
investigate this objective. These data were fitting because many of the study participants were at
risk for lung function decline due to high rates of smoking and the study also offered long
follow-up for COPD morbidity, and mortality due to COPD, coronary heart disease, and allcauses. The first study was designed to examine the relative contributions of lung function
decline and respiratory symptoms in predicting the adverse health outcomes. The first study
relates to workplace respiratory disease prevention programs where spirometry testing and a
respiratory symptom questionnaire are often used. The results of the first study indicated that
lung function decline was associated with increased risks of COPD morbidity and mortality, that
the effect was greater than for respiratory symptoms and asthma, emphasizing the potential
usefulness of monitoring for lung function change over time for prevention in at-risk
occupational populations. The second study investigated morbidity and mortality risks in two
areas that are not well investigated: in younger individuals, and in relation to long-term patterns
of lung function decline. The results indicated that increased lung function decline in individuals
age 45 years or younger and the persistency of accelerated lung function decline over follow-up
time were significant predictors for increased respiratory morbidity and mortality. The third
study evaluated whether the combined effect of the level of lung function at baseline and
subsequent rate of lung function decline could further identify high-risk groups. The results
showed that the combined effect of a decreasing level of baseline forced expiratory volume in
one second (FEV1b) and increasing FEV1 decline was associated with progressively greater
morbidity and mortality risks. Groups with ‘normal’ lung function but accelerated declines had
significantly increased mortality risks, including never smokers and individuals 45 years or
younger. The results of these three studies using an at-risk population demonstrate the potential
for COPD morbidity and mortality prevention through monitoring for lung function decline in
males, females, never smokers, younger individuals, and those with ‘normal’ lung function.
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Chapter 1
1.1

Introduction

Excessive lung function decline is a marker of an underlying adverse health condition that may
lead to the development of chronic obstructive pulmonary disease (COPD), the fourth leading
cause of death in the United States and broadly defined as irreversible airflow limitation mainly
caused by chronic bronchitis and emphysema, but asthma can in some situations also lead to
COPD. The principal risk factor for COPD is tobacco smoking, but environmental factors,
including occupational exposures also contribute to the development of COPD.1 Prevention of
this disease due to occupational exposures is one of the major long-term goals of the National
Institute for Occupational Safety and Health (NIOSH).2 The goal of this study is to evaluate the
epidemiologic nature and utility of longitudinal measurements of forced expiratory volume in
one second (FEV1) as predictors for COPD, COPD or coronary heart disease (CHD) mortality,
and all-cause mortality in an aging, at-risk, population-based sample. Results of this evaluation
will be applicable to community and workplace screening of at-risk individuals for respiratory
disease and in the secondary prevention of disease.
COPD is generally a preventable disorder and involves progressive airflow limitation that is not
fully reversible and includes chronic bronchitis, emphysema, and small airways disease. Asthma
may also lead to irreversible airflow limitation identical to that of patients with COPD. Chronic
bronchitis is defined clinically as a productive cough occurring on most days for at least three
months during two consecutive years with no other identified causes for the symptoms.
Emphysema is defined as permanent expansion of the airspaces distal to the terminal bronchioles
and destruction of the walls in these airspaces, but without evident fibrosis. Small airways
2

disease is associated with inflammatory processes in the lungs that lead to the deposition of
collagen and thickening in the walls of the airways.1
Respiratory health monitoring can include periodic spirometry tests, administration of a
respiratory symptom questionnaire, or radiological tests.3, 4 Spirometry monitoring involves the
evaluation of the level of lung function and the rate of lung function decline for the individual as
well as for the group. For a group evaluation, differences in the level of lung function among
groups can be estimated with a cross-sectional study design and multivariate linear regression
analysis. The assessment of the influence of the rate of lung function decline on morbidity and
mortality requires a longitudinal study and multivariate statistical methods that account for time
to an event, such as Cox regression.
In the determination of whether an individual‟s lung function is within the normal limits, the
level of lung function can be compared to reference values, based on the average level of lung
function observed in healthy nonsmoking persons of the same age, sex, height, and
race/ethnicity. When an individual‟s level of lung function falls below the lower limit of normal
(LLN), the lung function level is considered abnormal. The LLN approximates the one-sided
95% confidence limit for the expected value, where 5% of apparently healthy individuals who
have never smoked would be identified as abnormal. The methods for evaluation of the rate of
decline in individuals in prospectively collected spirometry data as done in spirometry
monitoring are not that well-established and are a subject of NIOSH current research.5, 6
Questions remain about the usefulness of periodic spirometry and the screening criteria that
would maximize its efficacy for disease prevention.
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In conducting research on spirometry monitoring, the longitudinal data collected in the
Copenhagen City Heart Study were used to perform an epidemiological assessment of lung
function decline as a predictor of adverse outcomes. The current study also investigated the
relative effects of the level of lung function, the rate of decline, respiratory symptoms, and
asthma as predictors of adverse outcomes. Results may provide answers to some of the
remaining questions related to the development of guidance for effective intervention measures.

1.1.1 Incidence, Prevalence, and Costs of COPD
The World Health Organization estimates that worldwide 80 million people suffer moderate to
severe COPD. COPD deaths in 2005 totaled more than 3 million people or 5% of all deaths, with
nearly 90% of these COPD deaths occurring in middle and low-income countries. While COPD
has been more common in males, the gender gap has been narrowing with increased tobacco use
and exposure to biomass among females. As of 2002, COPD was the fifth leading cause of death.
A 30% increase in COPD deaths in the following decade was projected without a reduction of
the risk factors. By 2030, COPD is projected to be the third leading cause of death.7
Chronic lower respiratory diseases (International Classification of Diseases [ICD]-10 codes J40J47) were the fourth leading cause of death in the United States in 2005; COPD was the
underlying cause of 126,005 deaths among adults age 25 or above. The crude death rate was 65.1
per 100,000 population and the age-adjusted death rate was 64.3 per 100,000 population.8 An
estimated 10 million adults reported physician-diagnosed COPD in the United States in 2000,
while the National Health and Nutrition Examination Survey (NHANES) III estimated that 24
million adults may have impaired lung function, suggesting that COPD is largely
underdiagnosed. In 2000, COPD accounted for 8 million physician office and outpatient visits,
4

1.5 million emergency department visits, and 726,000 hospitalizations.9 The estimated cost of
COPD in the United States in 1998 was $26 billion.10 Using NHANES III to model an adjusted
relationship between COPD and labor force participation in the United States, people with
COPD were 3.9% less likely to be in the labor force than those without the disease. The estimate
of 1994 work loss due to COPD was $9.9 billion in the United States.11

1.1.2 Contribution of Occupational Exposures to COPD
Recent population-based studies demonstrate the contribution of occupational exposures to
COPD. Balmes‟ (2003) review indicates that approximately 15% of asthma and COPD is likely
to be related to occupational exposure.12 Leigh (2002) estimated 15,032 occupational COPD
deaths in 1996 assuming a 15% population attributable risk (PAR). Using data from the National
Hospital Discharge Survey and the Healthcare Cost and Utilization Project Nationwide Inpatient
Sample, the prevalence estimate was 2,395,650 for chronic bronchitis and emphysema combined
(COPD) in 1996 due to occupational exposure. Related costs were estimated at $5.0 billion.10
Based upon NHANES III data, the estimated attributable percent of COPD in the United States
working population aged 30–75 years was 19% overall and 31% for never smokers.13 In a 2003
study of older adults (55–75 years) who were surveyed about their health status, prior cigarette
smoking, and occupational exposures, the estimated PAR for occupational exposure after
adjusting for cigarette smoking was 20% for persons who reported a diagnosis of COPD, chronic
bronchitis, or emphysema and 31% for persons who reported COPD or emphysema.14
Longitudinal studies estimate that after adjustment for age and smoking, the annual decline in
FEV1 due to occupational exposures is about 7–9 milliliters per year (ml/yr) and the effect of
dust exposure may be greater than that of cigarette smoking alone for heavily exposed workers.12
5

1.1.3 Risk Factors for Lung Function Decline
While risk factors are not the focus of this study, they define the populations at risk for
accelerated lung function decline and that may benefit from screening and intervention activities.
The American Thoracic Society/European Respiratory Society task force emphasized a number
of host factors (genetic, gender, airway hyperreactivity, immunoglobulin E, and asthma) and
exposures (smoking, socioeconomic status, occupation, environmental pollution, perinatal events
and childhood illness, recurrent bronchopulmonary infections, and diet) that place individuals at
risk for COPD.1 Additional host factors that can increase the risk of lung function decline include
preexisting lung diseases such as tuberculosis or pneumonia and abdominal adiposity.15 This
wide range of risk factors, to which a great number of individuals are exposed, helps explain the
importance of lung function decline as a public health problem that is reflected in COPD as a
leading cause of mortality.

1.1.4 Occupational Risk Factors for COPD
Reviews over the years reveal the increasing knowledge on the many occupational risk factors
including coal mining, gold mining, uranium mining, pyrite mining, foundry work, steel work,
furnace and chemical work, textile manufacturing, grain and vegetable-product work, and
toluene diisocyanate work that are among the risky occupations.16 Airflow limitation due to
dusty occupations lead to research on the relationships of acute and chronic disease relative to
many airborne pollutants.17 Evidence on the risks of dust and dust and fumes was gathered from
various types of studies18 and occupational dust was identified as a cause of chronic bronchitis,
lung function decline, and increased risk of COPD in smokers.19
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Hendrick et. al. surmised that occupation can exert a COPD effect that varies by industry, level
of exposure, and substance; that interactions with smoking are probable; that multiple
environmental agents may cause COPD; and that COPD would be infrequent if both smoking
and asthma were absent.20 Dimich-Ward et. al. identified an association between inorganic dusts
and chronic airflow limitation, separate from pneumoconiosis.21 Coggon and Newman Taylor
concluded that there was strong evidence of lung function impairment and disability from coal
mine dust exposure, and an additive effect between coal mine dust and smoking on FEV1.22
Evidence on the association between COPD and silica dust exposure suggested that chronic
long-term exposure can lead to COPD, that the association between cumulative exposure and
airflow obstruction was independent of silicosis, and that smoking augments the effect of silica
dust on airflow obstruction and COPD deaths.23 The association between COPD and
occupational exposures has been found in hard-rock miners, tunnel workers, concretemanufacturing workers, and in non-mining industrial workers. Epidemiologic studies
demonstrate a relationship between dust exposure and the degree of emphysema in coal and
hard-rock miners.12

1.1.5 Longitudinal Studies of Lung Function Decline and Impairment
Several studies have examined FEV1 decline or impairment as a predictor of morbidity and
mortality. The risk of all-cause mortality has been frequently investigated,24-34 but risks for
mortality due to cardiovascular and coronary heart disease,28, 35-38 cancer, lung cancer, stroke,
and respiratory disease28, 36 have also been explored. There are fewer studies of the risks for
COPD incidence and hospitalizations.33, 34, 39 In these prior studies, the study designs focused
upon identifying lung function decline as an independent risk factor. Models were adjusted for a
range of other risk factors, as appropriate to the outcome under study, including age, sex, race,
7

height, weight, body mass index, baseline FEV1, average FEV1, shortness of breath on exertion,
attacks of shortness of breath, smoking and/or pack-years, years since smoking cessation,
occupational exposures to dust and to variable heat, hypertension, diabetes, coronary heart
disease, cardiovascular disease risk factors, cholesterol levels, depression, blood group, number
of infants delivered, alcohol intake, physical activity level, education, and social class.
As these previous studies have demonstrated ample statistically significant associations between
lung function decline and the risks of morbidity and mortality while adjusting for other risk
factors, the current study uses these results as a basis to investigate lung function decline as a
predictor of morbidity and mortality in minimally-adjusted models. These models were intended
to be informative for prevention practices based on observed lung function decline. Models in
the current study were adjusted for age, height, and baseline lung function and stratified by
gender, conducted for never smokers, and stratified by baseline age at spirometry testing to
consider major biological factors determining lung function and the principal risk factor for
COPD, tobacco smoking, that was highly prevalent in the study sample.

1.1.6 Occupational Longitudinal Studies of Lung Function Decline
In an early study of French industrial workers with 12 years of follow-up for men aged 30 to 54,
the individual annual rate of decline was estimated from measurements in 1960 and 1972. The
FEV1 slope was significantly related to exposure to mineral dust and grain dust, with a doseresponse relationship, and to heat exposure. Among those heavily exposed, slopes for workers
who changed jobs fared better than those who did not. Across various exposures to dust, gas, and
heat, average slopes ranged from 44–60 ml/yr after adjusting for age, smoking, and FEV1 level.40
Data from the United States National Coal Study demonstrated losses in FEV1 related to
8

smoking (0.1 liter over 11 years) and occupational exposure (0.036-0.084 liter over 11 years),
confirming findings in a study of British coal workers.41
A Swedish study of mortality in 300,000 construction workers identified a significantly higher
risk of COPD mortality for workers exposed to fumes and mineral dust.42 Among paper pulp
workers, the relationship between ozone exposure and lung function was examined. Increased
risks for declines in FEV1 and forced vital capacity (FVC) were found with reported chlorine
dioxide/sulphur dioxide gassings.43 In a study of the effects of exposure to silicon metal and
alloys through smelting on lung function, line operators working in the ferrosilicon/silicon metal
and silicon carbide smelters had sharper annual lung function decline in comparison to nonexposed workers.44 The effect of ongoing fume and dust exposure was studied on the rate of
progression of COPD for individuals in its early stages. Fume exposure was associated with
reduced post-bronchodilator FEV1 percent predicted in males, but was not associated with the
rate of decline in prebronchodilator FEV1. There was a nonstatistically significant trend in the
association of dust exposure with lower prebronchodilator FEV1 in females. This suggests a
sensitivity to fume exposure and that occupational exposure to fume in individuals with COPD
adversely affects lung function.45 A study of the effects of smoking and occupational exposure
on COPD identified higher incidence and prevalence of COPD in smokers with occupational
exposures to dusts, fumes, and vapors after 5 and 10 years as compared to workers with one or
neither exposure, and an interaction was identified between the exposures.46
Respiratory symptoms and reduced lung function were associated with an increased dropout rate
in a longitudinal study of Norwegian smelters. The most recently reported symptoms were more
predictive of dropout than those reported at baseline; shortness of breath was the most important
9

symptom.47 A study on the relationship between lung function and occupational dust exposure in
smelter workers demonstrated that annual change was negatively associated with increasing
exposure.48
1.2

Gap in the Literature

Although spirometry monitoring is recommended in workplaces where workers are exposed to
respiratory hazards, there are very few recommendations on methods for using spirometry results
in the prevention of respiratory disease. Since the mid 1970s, various spirometry monitoring
programs have been implemented and longitudinal spirometry data are now available to help
develop such methods and recommendations. Further examination of longitudinal spirometry
data is needed, including a comparison of questionnaire-reported symptoms versus spirometry to
provide a scientific basis for the development of recommendations to enhance community and
workplace screening of at-risk individuals in the prevention of respiratory disease. The objective
of the current study relates to three Healthy People 2020 Respiratory Disease, Chronic
Obstructive Pulmonary Disease objectives.49

RD–10: Reduce deaths from chronic obstructive pulmonary disease (COPD) among
adults.
RD–11: Reduce hospitalizations for chronic obstructive pulmonary disease (COPD).
RD–13: (Developmental) Increase the proportion of adults with abnormal lung function
whose underlying obstructive disease has been diagnosed.
The objective also generally relates to a goals of the National Institute for Occupational Safety
and Health to prevent and reduce work-related COPD.2 Importantly, decreasing rates of smoking
10

in the working population will result in increasing significance of occupational exposures
causing COPD50 and greater need for a more precise understanding of the occupational
contribution to COPD and how to best recognize future disease using prospectively collected
data.
The studies in Chapters 2–4 are secondary data analyses of the Copenhagen City Heart Study
longitudinal spirometry data and self-reported respiratory symptom and asthma data. These data
were used to estimate risks of COPD, COPD or CHD mortality, and all-cause mortality in a
population-based sample at risk for these outcomes, given the high prevalence of smoking in
both males and females. The study in Chapter 2 examines the relative contributions of lung
function decline and respiratory symptoms and asthma in predicting these outcomes with
particular relevance to workplace respiratory disease prevention programs, where longitudinal
spirometry and respiratory symptom questionnaires are primary tools used to identify respiratory
disease. This study also compares morbidity and mortality risks associated with multiple
measures of longitudinal lung function decline: the FEV1 slope; the FEV1 relative slope; the
American College of Occupational and Environmental Medicine‟s (ACOEM) Longitudinal
Normal Limit (LNL); and a 90 ml/yr limit.51, 52 The study in Chapter 3 evaluates two issues not
fully explored in the literature: 1) associations of lung function decline and respiratory symptoms
and asthma with morbidity and mortality in individuals younger than middle age (when COPD
typically becomes evident); and 2) associations with long-term patterns of decline and
symptoms. The study in Chapter 4 uses a novel approach to assess the combined effect of the
baseline level of lung function and subsequent lung function decline on morbidity and mortality
risks to help further identify high-risk groups.
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In summary, there is limited research using minimally-adjusted models to explore a more direct
relationship of lung function decline as a predictor of morbidity and mortality. Earlier studies
focused on estimating the adjusted relationship of lung function decline to morbidity and
mortality, to establish it as an independent risk factor. Our studies adjusted only for essential
covariates that would typically be available and taken into consideration in a clinical context53
and build upon the existing evidence of increased risks associated with lung function decline.
These minimally-adjusted models permit a different evaluation of lung function decline, one
with clinical implications for prevention and intervention based on observed lung function
decline.
These studies advance scientific knowledge by offering estimates of morbidity and mortality
risks due to lung function decline, and also the level of lung function, and self-reported
respiratory symptoms and asthma in a large, at-risk, aging, population-based sample. Estimates
were identified in males, females, never smokers, individuals above and below middle age, and
those with a ‘normal’ level of lung function, but excessive lung function decline. The
associations identified in this study may be useful for health care providers who evaluate lung
function decline in patients. This research increases knowledge relevant to the assessment of
longitudinal lung function decline and to the integration of respiratory symptom questionnaire
data into the decision-making process on prevention and intervention strategies. These studies
strengthen the rationale and broaden the scientific basis for the development of recommendations
to enhance screening for respiratory disease.

12
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Chapter 2
2.1

Introduction

Studies of various populations demonstrate that lung function can predict adverse health
outcomes, such COPD morbidity and mortality, CHD mortality, and all-cause mortality.24-34, 39,
54-57

COPD is a costly disease, with high prevalence rates in the United States and

internationally, high associated healthcare costs, early retirement from work, and excess
premature mortality. COPD is also associated with CHD, another costly disease.7, 10, 11, 36, 58-61
While the principal risk factor for COPD is tobacco smoking, occupational exposures also
contribute to the development of COPD and its cost.12-14, 36, 45, 46, 62-65 Industry-based studies
identify increased healthcare utilization and disability associated with COPD, and demonstrate
the need for prevention of excessive loss of lung function.66, 67 In workers with potential
exposure to occupational respiratory hazards, effective monitoring of longitudinal lung function
is one approach to early recognition of lung function impairment and provides opportunities for
developing prevention strategies to reduce potentially modifiable risk factors associated with
long-term adverse health outcomes.
Periodic lung function evaluation can support effective prevention strategies in the workplace.
Important issues to consider are: the critical rate at which lung function decline becomes a
significant predictor of morbidity and mortality; the measures of lung function decline that best
predict morbidity and mortality; and the role of respiratory symptoms and asthma in the
prediction. Specific cut-points in the FEV1 rate of decline were considered in a previous study of
mortality in coal miners.68 This study showed increased mortality risk with rates of decline above
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about 60 ml/yr in never smokers and with declines of 90 ml/yr in all miners; furthermore, the
decline of 60 ml/yr or more was associated with increased disability and early retirement.36
The aim of this study was to evaluate the risks of COPD morbidity based on hospitalizations,
COPD or CHD mortality, and all-cause mortality associated with excessive lung function
decline, current respiratory symptoms of chronic bronchitis and shortness of breath, and current
asthma in an aging community cohort. Specific objectives were to evaluate the usefulness of
various measures of lung function decline in predicting morbidity and mortality, to investigate
the critical rate of lung function decline that becomes a significant predictor of morbidity and
mortality, and to assess the usefulness of current respiratory symptoms and asthma in predicting
morbidity and mortality relative to lung function level and decline.
2.2

Methods

2.2.1 Study Population
Our study used data from the Copenhagen City Heart Study, a prospective study of
cardiovascular disease in 23,000 males and females aged 20 years and older.69, 70 The study
involved four clinical examinations (including spirometry) and a self-administered questionnaire
conducted over a 28-year period (1976–78, 1981–83, 1991–94, and 2001–03). A minimum of
three spirometry tests were performed at each session, in a sitting position, using an electronic
spirometer (N 403 Monaghan, United States). At least two measurements had to be within 5% of
one another.69, 70 For analysis of lung function decline, we selected subjects who had spirometry
tests at examinations one and two, approximately five years apart. Change in FEV1 was
evaluated because it is the most useful measurement for assessing the rate of lung function
decline.71 Height measurements were collected as part of the physical examination. Age and
15

gender data were obtained from the Copenhagen Population Register at the time of study
enrollment. Smoking status was self-reported at each examination.
Current respiratory symptoms of chronic bronchitis and current asthma were self-reported at
examinations one and two, while shortness of breath was initially ascertained at examination
two. In preliminary univariate analyses, we identified asthma (“Do you suffer from asthma?”),72
chronic bronchitis (“Do you bring up phlegm, in the morning or during the day, for as long as
three months each year?”), and shortness of breath (“Do you often feel out of breath?”) as the
best predictors of future morbidity and mortality.
Morbidity data were from the National Patient Register, mortality data from the Civil
Registration System, and causes of death from the National Register of Causes of Death. Three
health outcomes were studied: 1) primary and secondary hospital diagnoses of COPD morbidity
(ICD-8 491–492, and ICD-10 J41–J44); 2) COPD or CHD mortality (ICD-8 410–414, and ICD10 I20–I25) as an underlying or contributing cause; and 3) all-cause mortality. (Denmark
transitioned directly from the 8th to the 10th revision of ICD in 1993.) COPD morbidity follow-up
was until 12/31/2003. Mortality follow-up was until 12/31/2006 for cause-specific mortality, and
until 8/11/2007 for all causes.

2.2.2 Statistical Methods
The Cox proportional hazards model was used to estimate the hazard (instantaneous event rate)
of morbidity or mortality in relation to lung function level and decline, respiratory symptoms,
and asthma, while adjusting for essential covariates that would typically be available and taken
into consideration in a clinical context.53 Analyses were conducted by gender and for never
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smokers. Additional Cox models using penalized splines were conducted for the overall cohort to
identify the rate of FEV1 slope at which morbidity and mortality risks began to increase. For
COPD morbidity, time to event (or censor) was calculated from examination two until COPD
diagnosis, death, or end of follow-up. For mortality, time to event (or censor) was calculated
from examination two until death or end of follow-up.
First, we evaluated the relationships of the level of lung function measurements by examination
(one or two) with morbidity and mortality. Models included quartiles of lung function level
(FEV1/height2),73 respiratory symptoms, asthma, and age. The highest lung function level (75th
percentile and above) served as the reference category. As the results were generally similar,
only examination two results are presented because shortness of breath was often statistically
significant (p < 0.05) and was unavailable at examination one.
Second, we evaluated the relationship of the rate of lung function decline, and respiratory
symptoms and asthma ascertained at examination two with morbidity and mortality, adjusted for
baseline age, height-adjusted baseline lung function (FEV1/height2), and height (Figure 2.1). In
separate analyses, we evaluated four measures of lung function decline: 1) the FEV1 slope (the
difference in FEV1 between examinations one and two, divided by the time between the
examinations) in quartiles; 2) the FEV1 relative slope (slope divided by baseline FEV1) in
quartiles; 3) the American College of Occupational and Environmental Medicine‟s (ACOEM)
Longitudinal Normal Limit (LNL) decline based on the American Thoracic Society‟s (ATS)
15% annual limit and an expected decline of 30 ml/yr;51 and 4) a FEV1 decline of 90 ml/yr or
more.52 The ACOEM LNL is designed to identify excessive declines during early years of
spirometry follow-up (1–8 years) when data are sparse and a reliable slope cannot be estimated.51
17

To identify trends in risk, we categorized the slopes into quartiles and used the quartiles with the
lowest rates of decline (75th percentile and above) as the reference categories. The risks
associated with excessive lung function decline, defined by the two longitudinal limits (LNL and
a decline of 90 ml/yr or more), were compared to subjects with ‘normal’ decline. The two limits
were compared for predicting risk, and for model fit using the Akaike‟s information criterion
(AIC).74
Preliminary analysis of mean FEV1 values by year of examination revealed a slightly excessive
increase in mean FEV1 in 1981 (n = 4,319), but not in 1982 (n = 5,353) or 1983 (n = 2,593), as
compared to mean FEV1 for baseline examinations in 1976–78. It is unknown to the authors
whether this increase in 1981 was due to early difficulties with the Monaghan spirometer that
was replaced with a dry wedge spirometer by examination three or to other issues.70 To adjust for
this increase, we reduced the individual FEV1 measurements for 1981 by a fixed value of 289 ml
for males and 201 ml for females to align the 1981 values with the 1976–78 and 1982–83 values.
The fixed values represent the average difference in FEV1 values from examination one to two
(for 1982 only), minus 30 ml to correct for annual loss from 1981 to 1982. Models excluding the
1981 values were conducted for a sensitivity analysis regarding this adjustment.
Copenhagen City Heart Study participants gave informed consent to participate and the study
was performed in accordance with the 2nd Helsinki Declaration and approved by the Danish
regional ethics committee. The present study was approved by the National Institute for
Occupational Safety and Health Human Subjects Review Board and the West Virginia
University Institutional Review Board. Analyses were conducted with PROC PHREG (p < 0.05)
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in SAS, version 9.2 (SAS Institute Inc, USA). Penalized splines were prepared in R software,
version 2.7.2.
2.3

Results

Three subcohorts (males, females, and never smokers) used in the Cox models are described in
Table 2.1. The table shows the duration of follow-up for morbidity and mortality (15–20 years),
the mean and quartile values for FEV1/height2 (level of lung function) and the two types of
slopes (lung function decline), and the frequency of symptoms and asthma. For never smokers,
we presented gender-specific quartiles because females represented 75% of the never-smoker
subcohort. (Sample sizes for the analysis of lung function decline were smaller because
members had to participate at both examinations one and two.) Baseline characteristics for
subjects who were lost to follow-up by examination two were a higher average age, lower
average FEV1/height2, and a higher percentage of self-reported current asthma, symptoms of
chronic bronchitis, and smoking.

2.3.1 COPD Morbidity
Estimated hazard ratios (HR) for COPD morbidity (hospital diagnosis of COPD) are presented in
Table 2.2. The level of lung function (FEV1/height2) was a significant predictor of COPD
morbidity for males and females starting from the second quartile. A similar, but less significant
trend was observed in never smokers, where significance was observed only at the fourth
quartile.
A similar increasing trend in COPD morbidity risk was seen for the FEV1 slope, except
significance began at the third quartile for never smokers. Females had the highest HRs for
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COPD morbidity for the slope, the relative slope, the LNL, and the 90 ml/yr limit (Figure 2.2a).
Results from the penalized spline analysis showed that the log HR for COPD morbidity (males
and females combined) started to increase at an FEV1 slope of –54 ml/yr (Figure 2.3a). The
parameter for the linear rate was highly significant (p < 0.0001).
Comparing results for the dichotomous outcomes, the LNL was significantly associated with
COPD morbidity for all three subcohorts, as was the 90 ml/yr limit. When compared using the
AIC,74 the fit of these two models were similar. The LNL limit provided a slightly better fit for
females, but the 90 ml/yr limit was slightly better for males and never smokers.
Respiratory symptoms and asthma were often significantly associated with COPD morbidity in
the models with the level of lung function and lung function decline. The risks associated with
chronic bronchitis and shortness of breath were higher than for asthma for males and females. In
never smokers, the risk associated with asthma was the highest with a four-fold increase.

2.3.2 Mortality Due to COPD or CHD, and All-cause Mortality
For mortality outcomes, there was significant association with decreasing level of lung function
for all three subcohorts (Tables 2.3 and 2.4). The risk of COPD or CHD mortality in relation to
the level of lung function was slightly higher than for all-cause mortality, with females and never
smokers often having higher risks than males. For COPD or CHD mortality, females in the
fourth quartile had more than a five-fold increase in risk, never smokers a nearly four-fold
increase in risk, and males a three-fold increase in risk as compared to the reference. Hazard
ratios for all-cause mortality were more similar for the three subcohorts.
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Increased risk of mortality began at the second quartile of the FEV1 slope and relative slope for
females, and most often at the third quartile for males and the fourth quartile for never smokers.
Figures 2.3b and 2.3c show the penalized splines for the slope for the mortality outcomes in
males and females combined. The nonlinear terms were significant (p = 0.01 for COPD or CHD
mortality and p = 0.0001 for all-causes) and the spline crossed above zero for the log HR at –72
ml/yr for COPD or CHD mortality and at –77 ml/yr for all-cause mortality.
As for the dichotomous criteria (the LNL and the 90 ml/yr limit), there were significant
associations with both mortality outcomes, with the exception of the LNL and COPD or CHD
mortality in never smokers. The AIC values for these two criteria were similar by subcohort and
outcome, but the models with the LNL fit best overall, with the exceptions of COPD or CHD
mortality in males and in never smokers. A comparison of all of the results by subcohort
demonstrates that females had the highest HRs for both mortality outcomes for all four measures
of lung function decline.
Asthma was not significantly associated with increased risk of mortality. Chronic bronchitis was
significantly associated with mortality, but not for never smokers; COPD or CHD mortality was
approximately 30% more likely for males and 60% for females who reported chronic bronchitis.
In the models with the level of lung function, shortness of breath was significantly associated
with mortality for all three subcohorts; doubling the risk of COPD or CHD mortality for males
and females, and increasing the risk of all-cause mortality by 50%. Similar results were observed
in the models with lung function decline.
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2.4

Discussion

Unlike studies concerned with identifying morbidity and mortality risk factors, our interest was
examining the relationship of respiratory status (lung function, respiratory symptoms, and
asthma) with morbidity and mortality. This study relates to clinical practice and prevention as it
focuses on the predictive, rather than causative, nature of these respiratory factors. The level of
lung function was associated with high risks for morbidity and mortality, supporting the need for
prevention. For example, in at-risk occupational populations, monitoring lung function over time
can be used to identify individuals at risk of lung function impairment and initiate appropriate
intervention. Our results add to current knowledge on lung function decline as a predictor of
morbidity and mortality in aging populations.

2.4.1 Evaluating the Usefulness of the Measures of Lung Function Decline
The results demonstrate the predictive capacities of the four criteria for lung function decline (the
FEV1 slope and relative slope, the ACOEM LNL based on the ATS 15% year-to-year limit, and a
FEV1 decline of 90 ml/yr or more) for morbidity and mortality.51, 52 Associations were stronger
with COPD morbidity, as might be expected, given its identification using a hospital diagnosis
which would focus on greater disease severity (Figure 2.2a). Also as expected, associations with
mortality due to COPD or CHD were slightly higher than with all-cause mortality (Figures 2.2b
and 2.2c); possibly due to a more direct relationship of COPD and CHD mortality with lung
function. Females were at greater risk of morbidity and mortality than males across all measures
of lung function decline. This may be partially explained by smaller lung capacity in females;
loss of lung function could pose more risk.75 Also, given that females in this study had lower
tobacco consumption than males, this may suggest higher susceptibility in females. Other studies
also find females more susceptible to the effects of smoking and with more rapid decline than
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males, and possibly with greater propensity for the development of COPD.76, 77 HRs for never
smokers showed an increasing trend for all outcomes, but less statistical significance (Tables
2.2–2.4).
Among the four criteria, quartiles for the slope had higher HRs, but goodness of fit (AIC) was
generally better for the relative slope. The slightly lower risk and better fit for the relative slope
are reasonable given the adjustment for baseline lung function level. As for the two limits (the
LNL and the 90 ml/yr limit), the HRs were similar, but often slightly higher for the LNL, and the
goodness of fit was often better for the LNL.

2.4.2 Investigating Critical Rates of Lung Function Decline
HRs for COPD morbidity suggest a critical rate at the third quartile of the slope with risks
greater than 2.5 times those for the reference (Figure 2.2a), corresponding to declines starting at
60 ml/yr for males and 57 ml/yr for females (Table 2.1). For COPD or CHD mortality, the
critical rate is more likely at the fourth quartile of the slope, with risks nearly doubled for males
and tripled for females (Figure 2.2b). For all-cause mortality, fourth quartile risks were increased
by 67% and 88% for males and females, respectively (Figure 2.2c), corresponding to declines
starting at 118 ml/yr for males and 95 ml/yr for females (Table 2.1).
Our results generally agree with several community-based and occupational studies of lung
function decline and respiratory morbidity and mortality.29, 33, 36, 57, 68 Similarities include slightly
higher increased risks in females of COPD hospitalization and all-cause mortality associated
with rapid decline as compared to males29, 33 and increased risk of cardiac mortality with
increasing decline in males.57 Also similar to our results, underground coal miners had a two-fold
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risk of cardiovascular and nonmalignant respiratory disease mortality with rapid decline,36 and
declines above 90 ml/yr were statistically significant for mortality as were declines of 60 ml/yr
or more in never smokers.68

2.4.3 Assessing the Usefulness of Respiratory Symptoms and Asthma Relative to Lung Function
Risks associated with lung function decline were often greater than with respiratory symptoms
and asthma, though their risks remained statistically significant after adjustment for lung
function. Asthma predicted COPD morbidity in males and never smokers. Chronic bronchitis
and shortness of breath predicted morbidity and mortality in males and females, with higher HRs
in females for chronic bronchitis which could relate to increased susceptibility to the effects of
respiratory hazards.77
Other studies have also reported increased risks of morbidity and mortality in relation to reported
respiratory symptoms (chronic bronchitis, cough, phlegm, and shortness of breath) and asthma,7882

even after controlling for FEV1.83 In contrast, we did not find increased risks between asthma

and respiratory mortality; however, our study targeted COPD specifically.78 Chronic bronchitis
often remained a significant predictor of mortality in our study, even with adjustment for
shortness of breath and height-adjusted baseline lung function.83
There are several limitations including the necessary adjustment in the FEV1 values collected in
1981. Therefore, influences of the adjusted data were investigated by excluding it from the
analysis, and significant overestimation of the HRs was not identified. Rather, the inclusion of
the adjusted data resulted in an underestimation of the HRs. In particular, COPD morbidity HRs
were underestimated for the level of lung function, the slope, and the relative slope, but mainly
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for never smokers and more often for females than for males. There was also underestimation of
the HRs for COPD or CHD mortality for the level of lung function for never smokers.
There are other possible limitations related to lung function decline. One is the use of only two
spirometry measurements for the rate of change in FEV1, leaving the slope vulnerable to
instability in either measurement, but the quartile groupings could have reduced this effect. The
limit of 90 ml/yr or more was from literature pertaining to males.52 Although females generally
have smaller lungs,75 results using this criterion were similar to those for the LNL and the fourth
quartile of the slope for females, a corresponding decline of 95 ml/yr or more. In studying lung
function decline, we did not account for possible mixing between cause and effect with regard to
steeply declining lung function and COPD outcomes, but our interest was in prediction rather
than causation.
Underdiagnosis of COPD and underreporting of COPD as a cause of death could have resulted in
misclassification, biasing the results toward the null, and reducing the associations.84 This was
addressed by combining the often interrelated COPD and CHD mortality into one outcome.60, 61
As COPD morbidity was limited to a hospital diagnosis, our results generally represent risks for
individuals with more severe disease, but also likely the highest costs. Other possible selection
bias includes subjects lost to follow-up by examination two who were older at baseline, had a
lower lung function level, and a higher proportion of self-reported current asthma, chronic
bronchitis, and smoking as compared those who participated at examinations one and two. This
could have resulted in an underestimation of risk.
Our findings are relevant to clinical and workplace disease prevention and cost-reduction.66, 67
Investment in health promotion and protection for COPD could create savings for employers.85,
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The strong associations of COPD morbidity with lung function level and decline correspond

with high medical costs for COPD and indicate that effective monitoring and interpretation of
lung function decline for early disease detection could lead to cost-savings.
In conclusion, the risks of COPD morbidity, COPD or CHD mortality, and all-cause mortality
showed an increasing trend with lung function decline after adjustment for baseline lung
function, respiratory symptoms, and asthma. The level and rate of lung function decline
generally demonstrated higher risks of morbidity and mortality than the respiratory symptoms
and asthma. These results provide further evidence that evaluation of lung function decline, in
addition to the lung function level, is important in spirometry monitoring programs.
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Examination 1
1976–78

Examination 2
1981–83

13,831 Subjects

12,166 Subjects

Study cohort:
9,679 Subjects

End of Follow-up
2003 2006 2007

979 COPD Morbidity

Spirometry and ascertainment
of asthma, chronic bronchitis,
and shortness of breath

1,770 COPD or CHD Mortality
5,800 All-cause Mortality

Figure 2.1 Sample size and morbidity and mortality follow-up. Above the timeline are the numbers of subjects who participated in spirometr y testing by Copenhagen
City Heart Study examination. Below the timeline is the number of subjects who participated in spirometry testing at examinat ions one and two and the numbers of
health outcomes that occurred during the morbidity and mortality follow-up periods. Note that the follow-up periods are represented as dashed lines. COPD morbidity
follow-up lasted until 2003. COPD or CHD mortality follow-up lasted until 2006. All-cause mortality follow-up lasted until 2007.
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Table 2.1 Characteristics of the subcohorts for Cox proportional hazards model analysis using data for lung function level and decline
Data for lung function level
Males
Females
Never smokers
(Examination two)
Subjects (n, %)*
Age at examination two (mean, SD†)

5,494

44.8

6,771

55.2

2,555

20.8

56.1

12.6

56.7

12.1

56.4

13.8

COPD morbidity

15.4

6.9

17.3

6.0

18.1

5.7

COPD or CHD mortality

16.9

7.9

19.3

7.0

20.0

6.7

All-cause mortality

17.1

8.1

19.5

7.2

20.3

7.0

Follow-up, years (mean, SD)

Height, cm† (mean, SD)

174

7

161

6

164

9

FEV1, l† (mean, SD)

2.82

0.91

2.05

0.63

2.39

0.85

FEV1/height2 x mean height2, l (mean, SD)

2.57

0.75

2.17

0.60

2.42

0.67

25th percentile

2.07

1.78

2.43; 1.87‡

Median

2.56

2.17

2.92; 2.23‡

75th percentile

3.08

2.58

3.41; 2.65‡

Asthma (n, %)

172

3.1

218

3.2

59

2.3

Chronic bronchitis (n, %)

872

15.9

722

10.7

148

5.8

Shortness of breath (n, %)

543

9.9

728

10.8

159

6.2

629; 1,926‡

24.6; 75.4‡

1,822

18.8

Never smokers (n, %)

629

11.5

1,926

28.5

Former smokers (n, %)

1,352

24.6

1,244

18.4

Current smokers (n, %)

3,510

63.9

3,592

53.1

4,253

43.9

5,426

56.1

Data for lung function decline
(Examination one to two)§
Subjects (n, %)*
Baseline age (mean, SD)

52.5

11.4

52.7

10.8

52.8

12.2

COPD morbidity

15.2

6.9

17.3

6.0

18.2

5.6

COPD or CHD mortality

16.7

7.9

19.3

6.9

20.1

6.7

All-cause mortality

16.9

8.1

19.6

7.1

20.4

Follow-up, years (mean, SD)

6.9

Baseline FEV1, l (mean, SD)

3.09

0.82

2.25

0.55

2.56

0.79

Baseline FEV1/height2 x mean height2, l (mean, SD)

2.83

0.67

2.40

0.53

2.62

0.62

Slope FEV1, ml/yr† (mean, SD)
25th percentile
Median
75th percentile
Slope FEV1/baseline FEV1, %/yr (mean, SD)

–62

94

–45

71

–43

–118

–95

–114; –94‡

–60

–57

–57; –40‡

0

0

19; 0‡

–2.0

3.4

–1.9

3.4

–1.5

25th percentile

–4.1

–4.1

–3.2; –3.8‡

Median

–2.2

–2.2

–1.5; –2.0‡

0.0

0.0

0.4; 0.0‡

75th percentile
FEV1 below LNL† (n, %)

80

3.4

743

17.4

1,016

18.7

346

19.0

1,717

40.4

1,444

26.6

505

27.7

Asthma (n, %)

125

2.9

168

3.1

40

2.2

Chronic bronchitis (n, %)

665

15.6

558

10.3

96

5.3

Shortness of breath (n, %)

401

9.4

550

10.1

104

5.7

FEV1 decline of 90 ml/yr or more (n, %)

*A total of 12,265 subjects at examination two and 9,679 subjects at examinations one and two.
†SD, standard deviation; cm, centimeters; l, liters; ml/yr, milliliters/year; LNL, Longitudinal Normal Limit.
‡Males; females.
§Includes subjects with approximately five years between spirometry tests.
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Table 2.2 Cox proportional hazards models for COPD morbidity (hospital diagnosis of COPD [ICD-8 491–492, ICD-10 J41–J44])
Males
Females
Never smokers
Data for lung function level*
(Examination two)

(n = 5,442; COPD = 563)
HR

(n = 6,735; COPD = 678)

95% CI

HR

95% CI

(n = 2,548; COPD = 73)
HR

95% CI

Q1 FEV1/height2

1.00

Q2 FEV1/height2

2.69

(1.73–4.18)

2.66

(1.85–3.83)

1.64

Q3 FEV1/height2

6.10

(3.99–9.33)

5.09

(3.57–7.25)

1.41

(0.46–4.34)

Q4 FEV1/height2

16.36

(10.67–25.07)

16.55

(11.65–23.53)

5.18

(1.81–14.80)

Asthma†

2.21

(1.66–2.93)

1.20

(0.91–1.58)

3.69

(1.67–8.15)

Chronic bronchitis†

2.04

(1.68–2.47)

2.05

(1.70–2.48)

2.35

(1.26–4.38)

2.48

(2.00–3.08)

2.77

(2.29–3.36)

2.36

(1.21–4.58)

Shortness of breath†
Data for lung function decline‡
(Examination one to two)

1.00

(n = 4,214; COPD = 442)
HR

1.00

(n = 5,402; COPD = 537)

95% CI

HR

95% CI

1.00

(0.55–4.87)

(n = 1,817; COPD = 49)
HR

95% CI

Q1 FEV1 slope

1.00

1.00

Q2 FEV1 slope

1.61

(1.18–2.19)

2.48

(1.89–3.27)

1.80

(0.73–4.45)

Q3 FEV1 slope

2.54

(1.87–3.45)

3.37

(2.55–4.44)

2.53

(1.01–6.33)

Q4 FEV1 slope

3.77

(2.76–5.15)

6.12

(4.63–8.10)

3.58

(1.34–9.62)

Asthma

1.41

(1.00–1.99)

0.80

(0.58–1.12)

4.45

(1.40–14.11)

Chronic bronchitis

1.92

(1.53–2.40)

2.24

(1.82–2.77)

2.00

(0.84–4.79)

Shortness of breath

2.00

(1.54–2.61)

2.22

(1.76–2.78)

0.69

(0.21–2.22)

Q1 FEV1 relative slope

1.00

Q2 FEV1 relative slope

1.50

(1.09–2.07)

1.99

(1.48–2.68)

1.73

(0.68–4.41)

Q3 FEV1 relative slope

2.17

(1.58–3.00)

2.60

(1.95–3.46)

1.65

(0.60–4.57)

Q4 FEV1 relative slope

3.48

(2.59–4.67)

5.27

(4.06–6.85)

3.92

(1.63–9.44)

Asthma

1.32

(0.93–1.86)

0.80

(0.57–1.11)

4.39

(1.38–13.92)

Chronic bronchitis

1.95

(1.56–2.44)

2.26

(1.82–2.79)

2.03

(0.87–4.73)

Shortness of breath

2.04

(1.57–2.65)

2.21

(1.76–2.78)

0.69

(0.22–2.18)

FEV1 below LNL

2.32

(1.86–2.88)

3.01

(2.49–3.64)

2.33

(1.22–4.44)

Asthma

1.52

(1.08–2.14)

0.86

(0.62–1.20)

4.49

(1.46–13.78)

Chronic bronchitis

1.98

(1.58–2.48)

2.37

(1.91–2.93)

2.18

(0.93–5.10)

Shortness of breath

2.10

(1.62–2.74)

2.27

(1.81–2.86)

0.76

(0.24–2.39)

FEV1 decline of 90 ml/yr or more

2.11

(1.73–2.57)

2.87

(2.37–3.48)

2.32

(1.19–4.53)

Asthma

1.48

(1.05–2.09)

0.82

(0.59–1.15)

4.74

(1.56–14.46)

Chronic bronchitis

2.02

(1.61–2.52)

2.34

(1.89–2.89)

1.97

(0.81–4.80)

Shortness of breath

2.12

(1.63–2.75)

2.38

(1.90–2.98)

0.78

(0.25–2.41)

1.00

1.00

*Models adjusted for age at examination two.
†Asthma, chronic bronchitis, and shortness of breath represented as dichotomous variables in all models.
‡Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2), and height. See Table 2.1 for quartile values.
FEV1 relative slope, slope FEV1/baseline FEV1; LNL, Longitudinal Normal Limit.
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Table 2.3 Cox proportional hazards models for COPD (ICD-8 491–492, ICD-10 J41–J44) or CHD mortality (ICD-8 410–414, and ICD-10 I20–I25)
Males
Females
Never smokers
Data for lung function level*
(Examination two)

(n = 5,494; Deaths = 1,201)
HR

(n = 6,771; Deaths = 983)

95% CI

HR

95% CI

(n = 2,555; Deaths = 269)
HR

95% CI

Q1 FEV1/height2

1.00

Q2 FEV1/height2

1.46

(1.15–1.85)

1.88

(1.38–2.57)

1.92

(0.95–3.89)

Q3 FEV1/height2

2.02

(1.60–2.56)

2.79

(2.06–3.77)

2.54

(1.29–5.01)

Q4 FEV1/height2

3.02

(2.38–3.84)

5.49

(4.07–7.41)

3.94

(2.00–7.76)

Asthma†

1.14

(0.88–1.47)

0.87

(0.66–1.15)

1.03

(0.49–2.14)

Chronic bronchitis†

1.32

(1.14–1.53)

1.62

(1.37–1.93)

1.32

(0.88–1.99)

2.15

(1.82–2.54)

2.30

(1.94–2.72)

1.57

(1.04–2.35)

Shortness of breath†
Data for lung function decline‡
(Examination one to two)

1.00

(n = 4,253; Deaths = 974)
HR

1.00

(n = 5,426; Deaths = 796)

95% CI

HR

95% CI

1.00

(n = 1,822; Deaths = 202)
HR

95% CI

Q1 FEV1 slope

1.00

1.00

Q2 FEV1 slope

1.20

(0.99–1.45)

1.48

(1.19–1.83)

1.17

(0.77–1.78)

Q3 FEV1 slope

1.34

(1.10–1.63)

1.73

(1.39–2.15)

1.42

(0.93–2.17)

Q4 FEV1 slope

1.91

(1.57–2.33)

2.95

(2.38–3.67)

1.42

(0.90–2.25)

Asthma

0.94

(0.70–1.27)

0.74

(0.54–1.03)

1.30

(0.56–3.03)

Chronic bronchitis

1.29

(1.10–1.52)

1.58

(1.31–1.92)

1.33

(0.80–2.22)

Shortness of breath

1.92

(1.58–2.33)

1.86

(1.52–2.28)

1.21

(0.70–2.09)

Q1 FEV1 relative slope

1.00

Q2 FEV1 relative slope

1.15

(0.94–1.40)

1.51

(1.21–1.90)

1.08

(0.69–1.67)

Q3 FEV1 relative slope

1.31

(1.07–1.60)

1.27

(1.00–1.60)

1.15

(0.74–1.80)

Q4 FEV1 relative slope

1.75

(1.45–2.11)

2.68

(2.19–3.28)

1.61

(1.06–2.43)

Asthma

0.90

(0.67–1.22)

0.68

(0.49–0.94)

1.31

(0.56–3.04)

Chronic bronchitis

1.29

(1.10–1.53)

1.60

(1.32–1.95)

1.32

(0.79–2.19)

Shortness of breath

1.95

(1.61–2.37)

1.90

(1.56–2.33)

1.17

(0.68–2.02)

FEV1 below LNL

1.56

(1.34–1.82)

2.14

(1.84–2.50)

1.34

(0.97–1.85)

Asthma

0.95

(0.70–1.28)

0.73

(0.52–1.01)

1.27

(0.55–2.95)

Chronic bronchitis

1.31

(1.11–1.54)

1.63

(1.34–1.98)

1.32

(0.79–2.21)

Shortness of breath

1.95

(1.60–2.36)

1.86

(1.51–2.27)

1.22

(0.71–2.10)

FEV1 decline of 90 ml/yr or more

1.54

(1.35–1.75)

2.12

(1.81–2.48)

1.43

(1.03–1.99)

Asthma

0.94

(0.70–1.27)

0.76

(0.55–1.05)

1.33

(0.57–3.08)

Chronic bronchitis

1.30

(1.11–1.54)

1.62

(1.33–1.96)

1.31

(0.78–2.18)

Shortness of breath

1.98

(1.63–2.39)

1.89

(1.55–2.31)

1.19

(0.69–2.05)

1.00

1.00

*Models adjusted for age at examination two.
†Asthma, chronic bronchitis, and shortness of breath represented as dichotomous variables in all models.
‡Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2), and height. See Table 2.1 for quartile values.
FEV1 relative slope, slope FEV1/baseline FEV1; LNL, Longitudinal Normal Limit.
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Table 2.4 Cox proportional hazards models for all-cause mortality
Males
Data for lung function level*

(n = 5,494; Deaths = 3,535)
HR

(Examination two)

95% CI

Females

Never smokers

(n = 6,771; Deaths = 3,632)

(n = 2,555; Deaths = 1,181)

HR

95% CI

HR

95% CI

Q1 FEV1/height2

1.00

Q2 FEV1/height2

1.27

(1.13–1.44)

1.39

(1.22–1.57)

1.54

(1.20–1.98)

Q3 FEV1/height2

1.60

(1.42–1.81)

1.83

(1.62–2.07)

1.70

(1.33–2.16)

Q4 FEV1/height2

2.31

(2.04–2.62)

2.65

(2.33–3.01)

2.15

(1.68–2.76)

Asthma†

0.98

(0.82–1.17)

0.99

(0.83–1.18)

1.13

(0.78–1.63)

Chronic bronchitis†

1.29

(1.18–1.40)

1.32

(1.20–1.46)

1.16

(0.94–1.44)

1.52

(1.36–1.70)

1.50

(1.36–1.67)

1.38

(1.11–1.70)

Shortness of breath†
Data for lung function decline‡

1.00

(n = 4,253; Deaths = 2,842)

(Examination one to two)

HR

1.00

(n = 5,426; Deaths = 2,958)

95% CI

HR

95% CI

1.00

(n = 1,822; Deaths = 860)
HR

95% CI

Q1 FEV1 slope

1.00

1.00

Q2 FEV1 slope

1.14

(1.02–1.27)

1.24

(1.12–1.39)

1.17

(0.95–1.43)

Q3 FEV1 slope

1.20

(1.08–1.35)

1.37

(1.23–1.53)

1.31

(1.06–1.61)

Q4 FEV1 slope

1.67

(1.49–1.87)

1.88

(1.68–2.10)

1.53

(1.23–1.91)

Asthma

0.87

(0.71–1.07)

0.96

(0.78–1.16)

1.15

(0.73–1.80)

Chronic bronchitis

1.24

(1.12–1.38)

1.27

(1.14–1.43)

1.10

(0.84–1.45)

Shortness of breath

1.43

(1.26–1.63)

1.36

(1.21–1.54)

1.27

(0.97–1.66)

Q1 FEV1 relative slope

1.00

Q2 FEV1 relative slope

1.10

(0.98–1.23)

1.25

(1.11–1.39)

1.18

(0.96–1.46)

Q3 FEV1 relative slope

1.23

(1.09–1.37)

1.22

(1.09–1.37)

1.13

(0.91–1.40)

Q4 FEV1 relative slope

1.55

(1.39–1.73)

1.81

(1.63–2.01)

1.59

(1.29–1.95)

Asthma

0.84

(0.68–1.04)

0.91

(0.74–1.10)

1.11

(0.71–1.74)

Chronic bronchitis

1.24

(1.12–1.37)

1.28

(1.15–1.44)

1.09

(0.83–1.44)

Shortness of breath

1.45

(1.28–1.65)

1.38

(1.22–1.55)

1.26

(0.97–1.65)

FEV1 below LNL

1.48

(1.35–1.62)

1.58

(1.46–1.72)

1.42

(1.22–1.66)

Asthma

0.87

(0.71–1.07)

0.94

(0.77–1.15)

1.11

(0.71–1.74)

Chronic bronchitis

1.25

(1.13–1.39)

1.30

(1.16–1.45)

1.11

(0.84–1.46)

Shortness of breath

1.44

(1.27–1.64)

1.36

(1.21–1.54)

1.29

(0.99–1.69)

FEV1 decline of 90 ml/yr or more

1.37

(1.27–1.48)

1.55

(1.42–1.68)

1.37

(1.17–1.61)

Asthma

0.87

(0.70–1.07)

0.97

(0.80–1.18)

1.14

(0.73–1.79)

Chronic bronchitis

1.25

(1.13–1.39)

1.29

(1.15–1.44)

1.10

(0.83–1.45)

Shortness of breath

1.47

(1.30–1.67)

1.37

(1.22–1.55)

1.29

(0.99–1.68)

1.00

1.00

*Models adjusted for age at examination two.
†Asthma, chronic bronchitis, and shortness of breath represented as dichotomous variables in all models.
‡Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2), and height. See Table 2.1 for quartile values.
FEV1 relative slope, slope FEV1/baseline FEV1; LNL, Longitudinal Normal Limit.
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2.2a. COPD Morbidity

2.2b. COPD or CHD Mortality

2.2c. All-cause Mortality

Figure 2.2 Cox proportional hazards model results by gender (♦ = males and ● = females) for (a) COPD morbidity, (b) COPD or
CHD mortality, and (c) all-cause mortality. Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2),
height, and respiratory symptoms and asthma as dichotomous variables. See Table 2.1 for quartile values. FEV1 relative slope,
slope FEV1/baseline FEV1; LNL, Longitudinal Normal Limit.
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2.3a. COPD Morbidity

2.3b. COPD or CHD Mortality

2.3c. All-cause Mortality

Figure 2.3 Cox proportional hazards model using a penalized spline for the FEV 1 slope, males and females combined. The spline
crossed above zero for the log HR at –54 ml/yr for (a) COPD morbidity, at –72 ml/yr for (b) COPD or CHD mortality, and at –77 ml/yr
for (c) all-cause mortality. Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2), and height. Tick
marks on the x axis represent the frequency of the various FEV1 slope values.
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Chapter 3
3.1

Introduction

Lung function is a significant predictor of increased COPD and CHD morbidity and mortality
and all-cause mortality.32-34, 37, 38 Spirometry is recommended for secondary prevention through
early detection of abnormal lung function.87 As COPD onset is typically during middle age,
spirometry testing is recommended for individuals age 45 or older who are current or former
smokers or with chronic environmental or occupational exposures. Spirometry testing is also
recommended for individuals who have respiratory symptoms that may suggest COPD, including
chronic cough, sputum production, wheezing, or shortness of breath on exertion.88, 89
Occupational respiratory health monitoring for obstructive lung disease can include spirometry
and/or administering a respiratory symptom questionnaire.3, 4 Longitudinal spirometry is
recommended for at-risk worker populations, many of whom have lung function above predicted
values, for early detection of excessive declines due to exposures such as occupational hazards
and tobacco smoking.51, 90 Prevention based on longitudinal spirometry interpretation requires
knowledge of morbidity and mortality risks associated with excessive lung function decline,
respiratory symptoms, and asthma.
COPD prevention91 is crucial with its prevalence, costs, and disability projected to increase with
aging populations,92-94 yet questions remain about the development and course of disease and
associated morbidity and mortality. The Lung Health Study demonstrated that sustained smoking
cessation leads to decreased rates of lung function decline.95 A more recent study of the natural
history of chronic airflow obstruction in cohorts beginning at adolescence and young adulthood
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demonstrated benefits of early smoking cessation over later cessation on the rate of FEV1 decline
and showed that susceptible smokers often had respiratory symptoms at a young age and/or a
respiratory diagnosis during follow-up.96 Another prospective study showed that low lung
function in young, non-asthmatic adults predicted airflow obstruction at middle age.97 In our
previous study, decreased level of lung function and increased rate of decline were both
associated with increased risks of hospital diagnosis of COPD, COPD or CHD mortality, and allcause mortality with 15–20 years of follow-up,98 suggesting that early COPD prevention is
beneficial.
The purpose of this study is to further investigate associations observed in our previous study
between respiratory health outcomes (lung function, current respiratory symptoms, and current
asthma) and subsequent COPD morbidity based on hospitalizations, COPD or CHD mortality,
and all-cause mortality.98 We studied the above associations using extended morbidity and
mortality follow-up. We also studied the effects of age when excessive lung function decline was
identified on the above associations, and the effects of the pattern and persistency of the
excessive lung function decline, respiratory symptoms, and asthma ascertained during 25 years
of spirometry follow-up on subsequent morbidity and mortality.
3.2

Methods

3.2.1 Study Population
The Copenhagen City Heart Study is a prospective study of cardiovascular disease in males and
females age 20 years and older with four examinations (1976–78, 1981–83, 1991–94, and 2001–
03). The initial sample (19,698) was supplemented with 500 subjects age 20–24 years at
examination two and 3,000 subjects age 20–49 years at examination three. Each examination
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included spirometry and a self-administered questionnaire. An electronic spirometer (N 403
Monaghan, United States) was used at examinations one and two and was replaced by a dry
wedge spirometer (Vitalograph, United Kingdom) at examination three. Three spirometric
measurements were collected at each examination with at least two within 5% of one another.
The highest values of FEV1 and FVC were included in the data set. Current asthma, current
respiratory symptoms of chronic bronchitis, and smoking status were ascertained by selfadministered questionnaire.72 Ascertainment of shortness of breath was initiated at examination
two and of cough and wheeze by examination three.
Morbidity data were from the National Patient Register. Mortality data were from the Civil
Registration System and causes of death from the National Register of Causes of Death. Health
outcomes in the current study were 1) primary and secondary COPD hospital diagnoses (ICD-8
491–492, and ICD-10 J41–J44); 2) COPD or CHD mortality (ICD-8 410–414, and ICD-10 I20–
I25) as the underlying or contributing cause; and 3) all-cause mortality. (Denmark transitioned
directly from the 8th to the 10th revision of ICD in 1993.) Follow-up was through 5/8/2009 for
COPD morbidity, 12/31/2006 for cause-specific mortality, and 5/17/2009 for all-cause mortality.
Further information on the Copenhagen City Heart Study is available elsewhere.69, 99

3.2.2 Statistical Methods
We used Cox proportional hazards models to investigate associations between lung function
decline and morbidity and mortality through three objectives: 1) reassessing the overall risks and
critical cut-points at which morbidity and mortality start to increase using extended follow-up
data; 2) evaluating the effect of age on the above associations; and 3) evaluating the effect of
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temporal patterns in lung function decline and reported respiratory symptoms on subsequent
morbidity and mortality. Figure 3.1 describes the subcohorts used for studying each objective.

3.2.2.1 Overall Risks and Critical Cut-points
We related lung function decline to morbidity and mortality using spirometry data from
examinations three and four (1991–94 and 2001–03) with extended morbidity and mortality
follow-up through 2009 to reassess the critical cut-points in lung function decline associated with
morbidity and mortality risks. These spirometry data are more in accord with recent American
Thoracic Society/European Respiratory Society standards (Figure 3.1, Objective 1).69 The midstudy change in model of spirometer prevented calculation of a regression slope using data from
all four examinations.98
Cox models were used to estimate the risks of morbidity or mortality in relation to quartiles of
height-adjusted baseline FEV1 (FEV1/height3, a power of height found appropriate for these
data),53 quartiles of FEV1 slope (difference in FEV1 between the two examinations, divided by
time between the examinations), respiratory symptoms (yes/no), and asthma (yes/no). The
reference category was the 75th percentile and above for lung function. Data for respiratory
symptoms and asthma were from examination four. Models were stratified by gender, conducted
for never smokers separately, and adjusted for baseline age and height. In addition, Cox models
using penalized splines identified specific rates of decline where risks for morbidity and
mortality began to increase for males and females combined.68, 100 These and the following
models were adjusted for baseline age, baseline FEV1/height3, and height.
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3.2.2.2 Effect of Age
To investigate the effect of age on the association between the respiratory outcomes and
subsequent morbidity and mortality risks, Cox models were stratified by the age at baseline
spirometry using an age threshold relevant to COPD development (≤ 45 and > 45 years).88, 89 For
never smokers, the age cut-point was 50 years. Quartiles of the FEV1 slope were calculated
separately for males, females, and never-smoker males and females. To obtain a sufficient
number of events by stratum, lung function measurements from examinations one and two
(1976–78 and 1981–83) (Figure 3.1, Objective 2) were used to establish the respiratory
outcomes. As in the previous study, sensitivity analyses assessed the adjustment to the FEV1
measurements for 1981.98

3.2.2.3 Effect of Temporal Patterns in Lung Function Decline
To determine the effect of temporal patterns in respiratory outcomes over the 1976–2003 period
on subsequent morbidity and mortality, Cox models included subjects present at all examinations
and their patterns of lung function decline and respiratory symptoms (Figure 3.1, Objective 3).
Temporal patterns were established using FEV1 slopes in two periods: 1) examination one to two
[1976–78 and 1981–83] and 2) examination three to four [1991–94 and 2001–03]. Slopes were
dichotomized as either less than or equal to the median (excessive decline) or above the median
(normal decline). Four temporal patterns of lung function decline were established: 1) normal
decline over both periods [reference category]; 2) excessive decline over period one only; 3)
excessive decline over period two only; and 4) excessive decline over both periods. Similar
patterns were established for respiratory symptoms with symptoms reported at examination two
corresponding to period one and symptoms reported at examination three or four corresponding
to period two. Baseline symptoms were excluded because shortness of breath was not
39

ascertained. Analyses were conducted with PROC PHREG (p < 0.05) in SAS, version 9.2 (SAS
Institute Inc, USA), and R software, version 2.7.2, for the penalized splines.
3.3

Results

Characteristics of the three subcohorts used for the study objectives (Figure 3.1) are shown in
Table 3.1. The table describes the number of subjects in each subcohort, duration of follow-up,
lung function and FEV1 slope values, and the frequency of respiratory symptoms and asthma.
Subjects lost to follow-up in objectives one (51.7%), two (21.1%), and three (78.0%) had a
higher average age, lower average FEV1/height3, and a higher percentage of self-reported current
asthma, respiratory symptoms, and smoking at baseline; each of these characteristics was
statistically different (p < 0.001) from those for the studied subjects. Loss to follow-up was
mainly due to mortality.

3.3.1 Overall Risks and Critical Cut-points in Lung Function Decline
Quartiles of the level of lung function (FEV1/height3) at examination three and the FEV1 slope
from examination three to four were associated with increasing risks of COPD morbidity and allcause mortality (Table 3.2). For the slope and COPD morbidity, risks were significantly elevated
at the fourth quartile, losses of –77 and –57 ml/yr or more in males and females, respectively.
For all-cause mortality, risks increased from the third quartile of the slope for males and females,
declines of –54 and –41 ml/yr, respectively. For symptoms and asthma, females had higher
associated risks for COPD morbidity than males. There were too few events to model COPD or
CHD mortality because of short follow-up (four-year average) and morbidity in never smokers
(six-year average). Based on penalized splines, the cut-points where morbidity and mortality
risks began to increase approximated an overall decline of –49 ml/yr (Figures 3.2a and 3.2b).
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3.3.2 Age-related Risks Associated with Lung Function Decline, Symptoms, and Asthma
Overall, there was an increasing trend in morbidity and mortality risks with increasing quartiles
of the FEV1 slope for both age strata and gender groups, after adjustment for baseline FEV1
(Table 3.3). The risks of COPD morbidity and all-cause mortality were elevated significantly
from the second quartile of the slope regardless of age in males and females, but these risks were
often highest in the younger female group. The risk of COPD or CHD mortality was significantly
elevated mainly for the highest quartile. Chronic bronchitis was a significant predictor of COPD
morbidity in males and females across both ages, and in younger never smokers, while shortness
of breath tended to be significant in males and older females for morbidity and mortality. For
never smokers, the risk of COPD morbidity was significantly increased in older individuals at
the highest quartile of the slope, while asthma and chronic bronchitis demonstrated the greatest
risks in the younger never smokers. Although there was often an increasing trend in the HRs,
they did not reach statistical significance.

3.3.3 Risks Associated with Temporal Patterns of Lung Function Decline and Symptoms
There was an increasing trend in COPD morbidity and all-cause mortality risks across the four
temporal patterns of the slopes from the first two and last two examinations (Figures 3.3a and
3.3b), but there were too few events to model COPD or CHD mortality. For both COPD
morbidity and all-cause mortality, the risks were higher and the trend was steeper for males.
Patterns for chronic bronchitis and shortness of breath demonstrated lower risks for morbidity
and mortality than the slope patterns. Overall, morbidity risks from respiratory symptoms were
greater than for mortality.
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There was not a clear increasing trend in risk with shortness breath with patterns 2, 3, and 4.
COPD morbidity risks in males were (no events for pattern 2), 3.20 (1.86–5.52), and 3.72 (1.01–
10.00) and in females these were 1.70 (0.52–5.54), 4.23 (2.65–6.75), 3.18 (1.43–7.04),
respectively. All-cause mortality risks were 0.41 (0.06–2.97), 1.83 (1.27–2.63), and 1.22 (0.52–
2.86) in males and 0.62 (0.20–1.95), 1.48 (1.05–2.09), and 1.72 (0.91–3.26) in females,
respectively. Asthma was excluded from these models because it did not contribute significantly.
The only significant HRs for never smokers were for all-cause mortality and slope pattern 2
[2.28 (1.18–4.42)] and pattern 4 [2.06 (1.04–4.07)].
3.4

Discussion

This study is a continued investigation of the relationship of respiratory health status (lung
function, respiratory symptoms, and asthma) with subsequent COPD morbidity and mortality.98
Extended outcome follow-up through 2009 permitted reassessment of critical cut-points where
lung function decline became associated with increased risks of morbidity and mortality, using
spirometry data from the last two examinations (1991–94 and 2001–03). We also investigated
the effects of age at which lung function decline was ascertained on the association and of
temporal patterns in lung function decline and respiratory symptoms on subsequent morbidity
and mortality. Our study results could be useful in clinical practice and disease prevention,
providing information about the predictive nature of lung function measurements, respiratory
symptoms, and asthma for morbidity and mortality. This study also adds to current knowledge on
respiratory status as a predictor of morbidity and mortality in younger and aging populations.
For prevention, it is important to establish the morbidity and mortality risks associated with the
lung function level and rate of decline. Our current results (based on data from examinations
42

three and four) are generally consistent with our previous findings (based on data from
examinations one and two),98 showing high COPD morbidity and mortality risks associated with
lower lung function levels and excessive decline (Table 3.2). Morbidity and mortality risks
increased with declines starting at –77 and –54 ml/yr in males and –57 and –41 ml/yr in females,
respectively (Table 3.2). A cut-point of –49 ml/yr was associated with both increased morbidity
and mortality risk, overall (Figures 3.2a and 3.2b). Outcome follow-up in the current study was
too brief to investigate risks in never smokers, as was possible in the previous study where we
found significant associations.
The current results are similar to those of prior studies of lung function decline and all-cause
mortality. There are very few population-based morbidity studies, even though morbidity
indicates the cost of disease, regardless of whether disease increases mortality. Parallels to earlier
studies include significant associations between FEV1 decline and COPD hospitalizations and
mortality, with some studies reporting higher associations for females than for males.27-29, 33 As
for cut-points of increased risk, our results for males demonstrated increased mortality risks
similar to those in a study of underground coal miners where the risk increased at –60 ml/yr and
was statistically significant at –90 ml/yr or more.68
Recent evidence indicates that individuals susceptible to COPD tend to have respiratory
symptoms and lower lung function at younger ages,96 but spirometry testing is usually
recommended for individuals 45 years of age or older. Our results for individuals 45 years of age
or younger demonstrate excessive decline was a significant predictor of morbidity and mortality
(Table 3.3), comparable to the risks for the older individuals. By gender and age, morbidity and
mortality risks were higher in females. Among younger individuals, females had higher risks,
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even with lower smoking prevalence, a possible manifestation of greater susceptibility to the
effects of smoking.76, 77
The high COPD morbidity and mortality risks associated with excessive lung function decline
found in younger individuals (≤ 45 years) is relevant to screening practices as spirometry testing
is currently recommended for individuals age 45 or older who are current or former smokers or
with chronic environmental or occupational exposures or for individuals who have respiratory
symptoms that may suggest disease.88, 89 Susceptible smokers in the Framingham Offspring
cohort tended to have respiratory symptoms at a young age and/or a respiratory diagnosis during
follow-up.96 In our study, symptoms of chronic bronchitis were significant predictors of COPD
morbidity in younger individuals. Given that lung function decline was a significant predictor of
morbidity and mortality after adjusting for asthma and respiratory symptoms in our study, and
that low lung function in young, non-asthmatic adults predicts airflow obstruction at middle
age,97 screening for abnormal lung function decline at earlier ages may be useful, especially in
at-risk occupational populations where spirometry-based medical monitoring is conducted. These
results also have implications for the criteria used to identify disease such as the GOLD Stage
criteria which generally tend to underdiagnose COPD in individuals younger than 50 years of
age.101
Although individuals susceptible to COPD development tended to have respiratory symptoms
and lower lung function at a young age,96 it is well-known that intervention on risk factors such
as smoking cessation helps to reduce the rate of lung function decline. Our results confirm that
excessive decline in those 45 years of age or younger is associated with increased, and possibly
preventable, morbidity and mortality. A question then arises about how risks associated with
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temporal patterns of lung function decline compare, such as early excessive decline followed by
normal decline versus persistent excessive decline when compared with normal lung function
decline.
Our results show increasing morbidity and mortality risks with increasing persistence of
excessive decline and respiratory symptoms in males and females. Even never smokers had a
two-fold mortality risk with persistent excessive decline. Detection of early declines, such as
these in the first 4–7 years, and intervention could help prevent the risks observed in the
temporal patterns that demonstrated even greater risk. The morbidity and mortality risks
associated with the temporal patterns of chronic bronchitis and shortness of breath did not
demonstrate a clear trend, but were often significant.
Among the study‟s limitations, the age-stratified analyses and those for temporal patterns in lung
function decline and respiratory symptoms included adjusted FEV1 values for 1981 as in the
previous study.98 From sensitivity analyses, the adjustment appears to have resulted in an
underestimation of the HRs. Three clear cases were the fourth quartiles of the slope for COPD
morbidity in males over age 45 and for COPD or CHD mortality in females age 45 years and
younger, and slope pattern 4 (excessive decline over both periods) for COPD morbidity in males.
Also, the morbidity and mortality follow-up for the temporal pattern analyses was relatively
short (six-year average), risks related to the patterns of lung function decline would likely
increase with longer follow-up and aging of the cohort.
Calculation of the slope using only two spirometry measurements could be susceptible to
measurement error, but if not excessive, the quartile groupings could have reduced this bias.
Misclassification was possible through underdiagnosis of COPD morbidity and underreporting of
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COPD mortality which would bias the results toward the null and weaken associations.84 We
combined COPD and CHD mortality to address this limitation, as these diseases are often
linked.60, 61 Generalizability of the COPD morbidity results is limited to individuals with more
severe disease because cases were defined by hospital COPD diagnosis. Risks of morbidity and
mortality could have been underestimated due to self-selection of healthier subjects into the
Copenhagen City Heart Study and due to subjects lost to follow-up, increasingly
overrepresenting healthier subjects over time.
In conclusion, this study showed that both the level of lung function and lung function decline
were significant risk factors for excess morbidity and mortality, demonstrating the need for
prevention on both. Intervention on excessive lung function loss could help prevent these
outcomes and prevent lung function impairment. Associations between lung function decline and
morbidity and mortality were also demonstrated at younger ages, providing evidence that serial
lung function testing before middle age may identify a number of at-risk individuals who could
benefit from medical intervention. The increasing morbidity and mortality risks associated with
the temporal patterns of lung function decline suggest that early detection of lung function
decline and appropriate intervention could result in substantial risk reduction.
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Examination 1
1976–78

Examination 2
1981–83

13,830 Subjects

12,354 Subjects

Examination 3
1991–94
9,521 Subjects

Objective 1
subcohort:
4,557 Subjects

Objective 2
subcohort:
10,311 Subjects

Objective 3
subcohort:
2,719 Subjects

Examination 4
2001–03

End of Follow-up
2006
2009

5,326 Subjects

Spirometry and ascertainment
of asthma, chronic bronchitis,
cough, shortness of breath,
and wheeze

219 COPD Morbidity
605 All-cause Mortality
1,347 COPD Morbidity

Spirometry and ascertainment
of asthma, chronic bronchitis,
and shortness of breath

1,857 COPD or CHD Mortality
6,537 All-cause Mortality

Spirometry and ascertainment
of chronic bronchitis and
shortness of breath

175 COPD Morbidity
510 All-cause Mortality

Figure 3.1 Sample sizes and morbidity and mortality follow-up by study objective. Above the timeline are the numbers of subjects who participated in spirometry testing by Copenhagen City Heart Study
examination. Below the timeline are the numbers of subjects who met the criteria for each objective and the numbers of health outcomes that occurred during the morbidity and mortality follow-up periods for
each objective. Note that the follow-up periods are represented as dashed lines and that follow-up for COPD or CHD mortality ended in 2006.
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Table 3.1 Characteristics of the subcohorts for the Cox proportional hazards model analysis
Males

Females

Never smokers

Subcohort 1: Subjects present for examinations three and four*
Subjects (n, %)†

1,924

Baseline age (mean, SD)

42.2

2,633

57.8

1,254

27.5

52.1

13.5

54.2

13.6

51.9

14.6

COPD morbidity

6.2

1.5

6.3

1.4

6.5

1.1

COPD or CHD mortality

4.2

0.8

4.3

0.7

4.3

0.7

All-cause mortality

6.3

1.4

6.4

1.2

6.5

3.17

0.63

2.87

0.63

Years of follow-up (mean, SD)

Baseline FEV1/height3 x mean height3, l (median, SD)

35

–41

27

1.1

3.46; 2.92‡

0.58; 0.58‡

–49; –38‡

34; 27‡

Slope FEV1, ml/yr (median, SD)

–54

Asthma (n, %)§

100

5.2

201

7.6

63

5.0

Chronic bronchitis (n, %)§

295

15.3

345

13.1

97

7.7

Cough (n, %)§

281

14.6

389

14.8

122

9.7

Shortness of breath (n, %)§

117

6.1

221

8.4

52

4.2

Wheeze (n, %)§

419

21.8

585

22.2

145

11.6

Never smokers (n, %)§

416

22.0

838

32.1

Former smokers (n, %)§

803

42.6

955

36.6

Current smokers (n, %)§

668

35.4

816

31.3

12.2

1,445

14.0

416; 838‡

33.2; 66.8‡

Subcohort 2: Subjects present for examinations one and two*
Subjects with baseline age ≤ 45 (or ≤ 50) (n, %†)

1,262

Baseline age (mean, SD)
Subjects with baseline age > 45 (or > 50) (n, %†)
Baseline age (mean, SD)
Slope FEV1, ml/yr (median, SD)¶

37.5
3,271

6.1
31.7

57.8

7.5

–59

91

37.6
4,333
57.4
–55

5.9
42.0
7.2

751
39.3
1,184
60.6

7.3
7.5
11.5
6.5

69

–57; –39‡

95; 71‡

60.2

718

26.4

9.4

44.7

10.1

Subcohort 3: Subjects present for all examinations*
Subjects (n, %†)
Baseline age (mean, SD)

1,081

39.8

43.6

9.8

1,638
45.0

Slope FEV1, ml/yr (median):
Examination one to two

–57

–39

–39; –39‡

Examination three to four

–55

–42

–50; –39‡

*Spirometry tests were 4 to 7 years apart from examination one to two and 7 to 12 years apart from examination three to four.
†A total of 10,311 subjects were present for examinations one and two, 4,557 for examinations three and four, and 2,719 for all examinations.
‡Males; females.
§Ascertained at examination four.
¶Overall median and standard deviation values, not age-stratified.
FEV1, forced expiratory volume in one second; l, liters; ml/yr, milliliters/year; SD, standard deviation.
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Table 3.2 Cox proportional hazards models for lung function decline (Examination three to four)*, †
Males
COPD Morbidity

(n=1,878; COPD=91)
HR

Q1 Baseline FEV1/height3

95% CI

1.00

Females

(n=2,554; COPD=128)
HR

95% CI

1.00

Q2 Baseline FEV1/height3

2.46

(0.47–12.81)

5.61

Q3 Baseline FEV1/height3

12.91

(2.93–56.82)

11.42

(2.64–49.38)

Q4 Baseline FEV1/height3

27.14

(6.12–120.31)

23.31

(5.29–102.66)

(1.25–25.13)

Q1 FEV1 slope

1.00

Q2 FEV1 slope

1.87

(0.93–3.73)

1.16

(0.65–2.10)

Q3 FEV1 slope

1.28

(0.60–2.72)

1.71

(0.99–2.97)

Q4 FEV1 slope

3.87

(1.99–7.55)

2.56

(1.55–4.24)

Asthma

1.75

(0.92–3.32)

2.48

(1.59–3.88)

Chronic bronchitis

1.11

(0.69–1.80)

1.62

(1.08–2.44)

Cough

1.44

(0.87–2.38)

1.80

(1.17–2.77)

Shortness of breath

1.60

(0.91–2.83)

2.18

(1.39–3.40)

Wheeze

2.53

(1.55–4.13)

2.03

(1.31–3.14)

All-cause Mortality

1.00

(n=1,924; Deaths=292)
HR

95% CI

(n=2,633; Deaths=313)
HR

95% CI

Q1 Baseline FEV1/height3

1.00

Q2 Baseline FEV1/height3

2.13

(1.20–3.77)

1.50

(0.77–2.91)

Q3 Baseline FEV1/height3

1.82

(1.03–3.22)

2.13

(1.12–4.06)

3

3.04

(1.72–5.36)

3.68

(1.92–7.07)

Q4 Baseline FEV1/height

1.00

Q1 FEV1 slope

1.00

1.00

Q2 FEV1 slope

1.00

(0.69–1.45)

1.19

(0.85–1.67)

Q3 FEV1 slope

1.63

(1.15–2.32)

1.53

(1.09–2.15)

Q4 FEV1 slope

1.96

(1.38–2.77)

1.91

(1.37–2.67)

Asthma

0.63

(0.38–1.06)

1.27

(0.86–1.87)

Chronic bronchitis

0.92

(0.68–1.26)

1.21

(0.89–1.65)

Cough

1.06

(0.75–1.50)

1.17

(0.84–1.63)

Shortness of breath

1.60

(1.10–2.33)

1.37

(0.97–1.95)

Wheeze

1.30

(0.96–1.77)

0.94

(0.69–1.28)

*Adjusted for baseline age and height.
†Asthma and respiratory symptoms ascertained at examination four and represented as dichotomous variables in the models.
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3.2a. COPD Morbidity

3.2b. All-cause Mortality

–49

Figure 3.2 Cox proportional hazards model using a penalized spline for the FEV 1 slope, males and females combined. The spline
crossed above zero for the log HR at –49 ml/yr for (a) COPD morbidity and for (b) all-cause mortality. Models adjusted for baseline
age, height-adjusted baseline lung function (FEV1/height3), and height. Tick marks on the x axis represent the frequency of the
various FEV1 slope values.
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Table 3.3 Cox proportional hazards models for longitudinal lung function (Examination one to two)*, †
Males

COPD Morbidity

Females

Never Smokers

Baseline Age
≤ 45 Years

Baseline Age
> 45 Years

Baseline Age
≤ 45 Years

Baseline Age
> 45 Years

Baseline Age
≤ 50 Years

Baseline Age
> 50 Years

(n=1,260; COPD=118)

(n=3,228; COPD=472)

(n=1,441; COPD=147)

(n=4,312; COPD=610)

(n=751; COPD=13)

(n=1,178; COPD=58)

HR

95% CI

HR

95% CI

95% CI

95% CI

95% CI

95% CI

1.30

(0.79–2.15)

1.59

(1.17–2.15)

2.18

(1.34–3.57)

1.78

(1.36–2.33)

0.82

(0.11–6.12)

1.29

(0.57–2.89)

Q3 FEV1 slope

1.93

(1.13–3.29)

2.40

(1.78–3.24)

2.16

(1.27–3.68)

2.80

(2.12–3.68)

2.96

(0.55–15.95)

1.37

(0.58–3.20)

Q4 FEV1 slope

2.09

(1.18–3.70)

4.03

(2.96–5.47)

5.76

(3.41–9.74)

4.57

(3.44–6.07)

2.99

(0.48–18.72)

2.86

(1.23–6.65)

Asthma

1.62

(0.56–4.65)

1.54

(1.10–2.16)

1.18

(0.57–2.43)

0.96

(0.69–1.35)

11.79

(2.22–62.63)

2.60

(0.80–8.42)

Chronic bronchitis

1.90

(1.20–3.02)

1.79

(1.43–2.24)

3.09

(2.01–4.75)

1.95

(1.59–2.40)

6.06

(1.18–31.19)

1.88

(0.82–4.31)

Shortness of breath

1.46

(0.75–2.85)

1.73

(1.32–2.26)

1.38

(0.85–2.26)

2.24

(1.80–2.80)

1.06

(0.11–9.87)

1.26

(0.49–3.23)

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

1.80

(0.99–3.25)

1.12

(0.92–1.36)

1.88

(0.79–4.45)

1.31

(1.04–1.65)

1.43

(0.24–8.46)

1.15

(0.75–1.76)

Q3 FEV1 slope

1.80

(0.92–3.53)

1.33

(1.09–1.63)

1.59

(0.60–4.23)

1.72

(1.36–2.17)

2.91

(0.55–15.53)

1.19

(0.77–1.83)

Q4 FEV1 slope

2.03

(1.03–4.00)

1.83

(1.50–2.25)

4.29

(1.72–10.72)

2.71

(2.14–3.44)

0.58

(0.05–6.62)

1.39

(0.88–2.19)

Asthma

2.09

(0.85–5.13)

0.91

(0.67–1.23)

1.08

(0.35–3.34)

0.66

(0.47–0.92)

1.79

(0.20–15.91)

1.14

(0.46–2.84)

Chronic bronchitis

1.07

(0.60–1.89)

1.33

(1.12–1.57)

1.88

(0.86–4.12)

1.50

(1.23–1.82)

3.81

(0.72–20.10)

1.15

(0.67–1.96)

Shortness of breath

3.58

(1.93–6.63)

1.80

(1.48–2.19)

1.78

(0.76–4.15)

1.97

(1.61–2.40)

2.32

(0.27–19.98)

1.24

(0.72–2.14)

95% CI

(n=3,271; Deaths=2,750)
HR

95% CI

1.00

(n=1,445; Deaths=293)
HR

95% CI

1.00

1.00

(n=1,184; Deaths=194)

Q2 FEV1 slope

HR

1.00

(n=751; Deaths=12)

1.00

(n=1,262; Deaths=406)

1.00

(n=4,333; Deaths=789)

1.00

Q1 FEV1 slope

All-cause Mortality

1.00

(n=1,445; Deaths=45)

1.00

HR

1.00

(n=3,271; Deaths=935)

1.00

HR

Q2 FEV1 slope

(n=1,262; Deaths=88)

1.00

HR

Q1 FEV1 slope

COPD or CHD Mortality

1.00

HR

(n=4,333; Deaths=3,088)
HR

95% CI

1.00

1.00

(n=751; Deaths=110)
HR

95% CI

HR

95% CI

Q1 FEV1 slope

1.00

Q2 FEV1 slope

1.05

(0.80–1.38)

1.16

(1.04–1.30)

1.51

(1.08–2.10)

1.23

(1.10–1.37)

1.13

(0.66–1.95)

1.12

(0.91–1.37)

Q3 FEV1 slope

1.43

(1.07–1.91)

1.20

(1.07–1.34)

1.53

(1.07–2.18)

1.38

(1.23–1.55)

1.33

(0.76–2.30)

1.12

(0.91–1.38)

Q4 FEV1 slope

1.77

(1.33–2.37)

1.58

(1.41–1.78)

2.15

(1.48–3.12)

1.89

(1.68–2.12)

1.38

(0.77–2.47)

1.42

(1.14–1.76)

Asthma

1.03

(0.54–1.99)

0.87

(0.70–1.07)

0.98

(0.54–1.77)

0.94

(0.76–1.15)

1.41

(0.49–4.06)

1.00

(0.62–1.61)

Chronic bronchitis

1.34

(1.03–1.76)

1.24

(1.12–1.38)

1.19

(0.80–1.76)

1.27

(1.14–1.42)

1.11

(0.40–3.06)

1.12

(0.86–1.47)

Shortness of breath

1.78

(1.24–2.56)

1.40

(1.23–1.60)

1.37

(0.93–2.01)

1.35

(1.20–1.52)

1.25

(0.53–2.99)

1.25

(0.96–1.63)

3

*Adjusted for baseline age, height-adjusted baseline lung function (FEV1/height ), and height.
†Asthma and respiratory symptoms ascertained at examination two and represented as dichotomous variables in all models.
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1.00

(n=1,184; Deaths=866)
1.00

3.3a. COPD Morbidity

3.3b. All-cause Mortality

Figure 3.3 Cox proportional hazards models for patterns in lung function decline and respiratory symptoms (examination one to two
and examination three to four) by gender (♦ = males and ● = females) for (a) COPD morbidity and (b) all-cause mortality. Temporal
patterns in the slope during the two follow-up periods: 1) normal decline over both periods [reference]; 2) excessive decline over
period one only; 3) excessive decline over period two only; and 4) excessive decline over both periods. Temporal patterns in
respiratory symptoms in the two follow-up periods: 1) absent in both periods [reference]; 2) present in period one only; 3) present in
period two only; and 4) present in both periods. Models adjusted for baseline age, height-adjusted baseline lung function
(FEV1/height3), and height.
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Chapter 4
4.1

Introduction

Lung function is a significant predictor of COPD and CHD morbidity and mortality and all-cause
mortality.24-39, 55-57, 102 Generally, the absolute level of forced expiratory volume in one second
(FEV1) is indicative of severity of airflow obstruction and COPD, while the rate of FEV1 decline
is a marker of disease progression. COPD is a costly, highly-prevalent disease worldwide7, 11, 58,
59, 103

and multifactorial in nature. COPD is generally caused by inflammatory processes in the

lungs initiated by hazardous exposures that may lead to chronic bronchitis, small airways
disease, or emphysema.1, 104
Both emphysema and small airways disease are associated with gradual loss of tissue elasticity
combined with collagen deposition, leading to airflow limitation.105 Changes usually occur
gradually, generally before abnormality can be detected with spirometry or radiology. Early
markers suitable for detection of the disease processes are not yet available for widespread
application, although research in this area is progressing.106, 107 Furthermore, the strong
association between COPD and cardiovascular disease suggests that impaired lung function
caused by inflammatory changes in the lungs may lead to increased systemic inflammation
contributing to non-pulmonary disease.108
COPD is complex, with several early indicators of risk, including airflow limitation, respiratory
symptoms, and asthma, and known risk factors such as smoking, and environmental and
occupational exposures. Spirometry testing is essential for diagnosis and monitoring of COPD
progression.1 Monitoring lung function over time in at-risk individuals can help identify
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underlying progressive disease before lung function becomes abnormal. Combining the results of
cross-sectional and longitudinal spirometry could be informative for early identification of
disease and allow for intervention on patterns that may be associated with increased morbidity or
mortality risks. This approach would be particularly important for individuals who have lung
function levels above predicted values.51, 90, 109, 110
The purpose of this study was to evaluate the morbidity and mortality risks associated with the
combined effect of the level of lung function and the rate of lung function decline. Lung function
categories, from baseline forced expiratory volume in one second (FEV1b) compared to predicted
values, and quartiles of FEV1 slope, were used to identify potential high-risk groups for
prevention. Furthermore, the relationship between the lung function categories and the
prevalence rates of respiratory symptoms was investigated.
4.2

Methods

4.2.1 Study Population
The Copenhagen City Heart Study is a 28-year cardiovascular disease study with four
examinations of males and females age 20 years and older. The primary sample (19,698) was
drawn randomly from the Copenhagen Population Register in five-year age groups. Clinical
examinations (with spirometry) and a self-administered questionnaire were conducted. An
electronic spirometer (N 403 Monaghan, United States) was used for examinations one and two
(1976–78 and 1981–83). At each examination, three spirometric measurements were obtained
with at least two within 5% of one another. The highest values of FEV1 and FVC were retained
in the data set. Age and gender data were from the Copenhagen Population Register at study
enrollment and height was measured during the clinical examination. Smoking status and current
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respiratory symptoms of chronic bronchitis were ascertained by questionnaire at each examination,

and shortness of breath was ascertained beginning at examination two.69, 72
Morbidity data were from the National Patient Register. Mortality data were from the Civil
Registration System and cause-specific mortality data were from the National Register of Causes
of Death. In the current study, health outcomes are 1) primary and secondary COPD hospital
diagnoses (ICD-8 491–492, and ICD-10 J41–J44); 2) COPD or CHD mortality (ICD-8 410–414,
and ICD-10 I20–I25) as the underlying or contributing cause; and 3) all-cause mortality.
(Denmark transitioned directly from the 8th to the 10th revision of ICD in 1993.) Follow-up lasted
through 5/8/2009 for COPD morbidity, 12/31/2006 for cause-specific mortality, and 5/17/2009
for all-cause mortality. Additional Copenhagen City Heart Study information is available
elsewhere.69, 99

4.2.2 Statistical Methods
We used Cox proportional hazards models to estimate morbidity and mortality risks associated
with the combined effect of the FEV1b and subsequent FEV1 slope (difference in FEV1 between
the first two examinations, divided by time between the examinations) with an average follow-up
of five years (Figure 4.1). Combinations of FEV1b in comparison to predicted values111 and
quartiles of FEV1 slope formed nine categories in a single variable representing a continuum of
respiratory health status (Figure 4.2). The reference category included individuals with the most
robust lung function. Analyses were based on FEV1 measurements because these are the most
effective for evaluation of lung function decline.71 Measurements from examinations one and
two (1976–78 and 1981–83) were used to achieve a sufficient number of health outcomes by
category.
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Hazard ratios (HR) were estimated and corresponding 95% confidence intervals (CI) were
constructed overall, by gender, for never smokers, and by baseline age (≤ 45 and > 45), an age
breakpoint related to COPD development.88, 89 Time to event (or censor) was from examination
two until COPD hospital diagnosis, death, or end of follow-up for COPD morbidity and until
death or end of follow-up for mortality. All models used gender-specific quartile values for the
FEV1 slope, and were adjusted for baseline age and height. Other possible confounders, such as
smoking, were not included because we were interested purely in the relationships of the lung
function categories with morbidity and mortality for prevention purposes.
We also calculated Spearman‟s rho rank correlation coefficients between the nine categories and
the overall prevalence rates of current respiratory symptoms of chronic bronchitis and shortness
of breath at examination two. Population attributable risks (PAR) were calculated with Levin‟s
formula112 for category 9 and jointly for categories 8 and 9 as an example of the potential
contribution of an accelerated slope in those with a ‘normal’ FEV1b. As in our previous study,
sensitivity analyses assessed the effect of an adjustment to FEV1 measurements for 1981 that
were initially higher on average than those at examinations one (1976–78) and two (1982 and
1983).98
All Copenhagen City Heart Study subjects gave informed consent to participate. The Study was
performed in accordance with the 2nd Helsinki Declaration and approved by the regional ethics
committee. Current analyses were approved by the National Institute for Occupational Safety
and Health Human Subjects Review Board and the West Virginia University Institutional
Review Board. All analyses were conducted with PROC PHREG (p < 0.05) in SAS, version 9.2
(SAS Institute Inc, USA).
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4.3

Results

The characteristics of the 10,457 individuals with spirometry testing at examinations one and two
are summarized by subcohort (males, females, and never smokers) in Table 4.1. The table
describes the sample sizes, duration of morbidity and mortality follow-up (16–21 years), genderspecific values for FEV1b and the quartiles of FEV1 slope, and smoking status. Of note are the
high prevalence rates of current and former smoking, making this largely an at-risk sample.
Individuals lost to follow-up by examination two (22.9%) had a higher average age, lower
average height-adjusted FEV1, and higher prevalence rates of self-reported current respiratory
symptoms of chronic bronchitis, current asthma, and smoking at baseline; each of these
characteristics was significantly different (p < 0.001) as compared to study subjects.

4.3.1 Overall Morbidity and Mortality Risks
Significant overall trends in the risks of morbidity and mortality outcomes across the nine lung
function categories are demonstrated in Figures 4.3a-c. Risks were higher for COPD morbidity
as compared to the mortality outcomes. Statistically significant increases in the morbidity and
mortality risks began at category 4 (FEV1b at or above predicted and the fourth quartile of the
slope). By category 8 (FEV1b below predicted but at or above the LLN and the fourth quartile of
the slope), HRs reached 7.29 (4.24–12.52) for COPD morbidity, 4.07 (2.70–6.13) for COPD or
CHD mortality, and 2.13 (1.80–2.53) for all-cause mortality. The PARs for category 8 and above
were considerably increased from those for category 9, even though the HRs were similar (Table
4.2). The overall prevalence rates of symptoms of chronic bronchitis and shortness of breath also
generally increased with worsening lung function categories (Figure 4.4). The Spearman‟s rho
rank correlations were both –0.98 (p < 0.0001).
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4.3.2 Morbidity and Mortality Risks by Gender, for Never Smokers, and by Baseline Age at
Spirometry Testing
Morbidity and mortality risks by gender and for never smokers are presented in Table 4.3. In
general, an increasing trend in the HRs across the lung function categories was also observed for
these subcohorts. By gender, the risk of COPD morbidity was higher overall for females, where
the risk was statistically significant starting at category 4 (FEV1b at or above predicted and the
fourth quartile of the slope). Among never smokers, there was a clear trend for increasing COPD
morbidity risk with worsening lung function category, however the risk was only significant with
category 9 (FEV1b below the LLN). When stratified by gender, females demonstrated higher
COPD or CHD mortality risks than males; this pattern was not as clearly seen for all-cause
mortality.
Morbidity and mortality risks stratified by baseline age (≤ 45 and > 45) at spirometry testing are
shown in Table 4.4. The general increasing trend in the HRs across the lung function categories
was found in both the younger and older age groups. Among each subcohort (males, females,
never smokers, and ages ≤ 45 and > 45), cause-specific and all-cause mortality risks were
significantly increased for those with ‘normal’ lung function (FEV1b at or above the LLN), but
with accelerated FEV1 decline (fourth quartile of the slope).
Throughout these models, our method of stratification by combinations of lung function level
and rate of decline created the potential for a relatively small sample size in the reference
category that could influence the results. For example, this may partially explain the genderspecific differences in the morbidity and mortality risks. To explore this issue, we created a new
reference category by combining categories 1 and 2. The addition of category 2 narrowed the
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gender gap in risks slightly and reduced the HRs. Cumulative incidence of morbidity and
mortality within each lung function category was calculated for males, females, and never
smokers to provide more information related to this issue (Figure 4.5). To test the possibility that
the elevated risks in those with ‘normal’ FEV1b was due to airflow obstruction, we repeated the
overall analyses excluding those with FEV1b above the LLN, but with a ratio of FEV1b/baseline
FVC (FVCb) below the LLN. The results changed very little.
4.4

Discussion

This study shows that excessive rates of FEV1 decline are associated with increased morbidity
and mortality risks, even with a ‘normal’ baseline FEV1 (Figure 4.3). Increasing trends in risk
were consistently identified with baseline FEV1 at or above the LLN and increasing quartiles of
decline in males, females, never smokers, and with a baseline age of 45 or under or above 45
(Tables 4.3–4.4). To estimate the contribution of an accelerated decline in those with a ‘normal’
FEV1, we calculated and compared the PARs112 for FEV1 below the LLN, and then jointly with a
‘normal’ FEV1 and the steepest declines (categories 8 and 9). The additional contribution was
12.0% for COPD morbidity (49.6–37.6%, Table 4.2), 9.6% for COPD or CHD mortality, and
7.1% for all-cause mortality; indicating that the contribution of accelerated FEV1 decline in those
with ‘normal’ FEV1 has public health significance.
Although previous studies show associations between morbidity and mortality and FEV1 and the
rate of decline,24-39, 55-57, 102 evaluating their combined effect is a new approach and adds to
current knowledge regarding prevention. Combining baseline FEV1 and the rate of decline, we
could investigate the importance of accelerated decline despite ‘normal’ baseline FEV1 (Figure
4.2). Similar to prior studies, we also identified higher morbidity and mortality risks among
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females (Table 4.3),29, 33 which may result from increased susceptibility to the effects of
smoking,77 and increased COPD morbidity risk with lower lung function at younger ages96
(Table 4.4).
Most chronic conditions affecting lung function progress and accelerate with age. With COPD,
chronic inflammatory processes in the lungs lead to elastic tissue loss and small airways
remodeling,105 progressive conditions starting years before abnormalities are detectible with
spirometry or radiology. It has been suggested that inflammation in the lungs may contribute to
systemic inflammation, promoting non-pulmonary disease, such as ischemic heart disease.108
Currently there are no useful early markers of these disease processes. Many individuals with
abnormal spirometry results may follow a normal trajectory with age, while others with ‘normal’
results may display excessive decline likely reflecting progressive disease. Early COPD
detection may be improved through longitudinal spirometry testing in at-risk populations
(smokers, occupationally-exposed groups, individuals with respiratory symptoms [Figure
4.4]).21,98 Well-established risk factors for excessive decline are similar to those for COPD
(smoking, asthma, childhood respiratory diseases, occupational and environmental exposures).1,
33, 34, 96

Longitudinal spirometry may identify individuals with a high level of lung function but

excessive decline, whose disease could progress undetected over many years and eventually lead
to increased morbidity and mortality risks (Tables 4.3–4.4).51, 109
Barriers to the implementation of longitudinal spirometry include cost, data standardization and
quality, and effective interpretation of results.109 However, longitudinal spirometry could result
in both future cost-savings in at-risk or previously-diagnosed populations and improved quality
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of life through interventions that preserve lung function. Additionally, computerized spirometry
data can facilitate data interpretation and higher data quality.113
Despite this study‟s strengths, such as a large, age-stratified population and long outcome
follow-up, there were limitations including the adjustment of FEV1 values for 1981.98 Sensitivity
analyses indicated under- and overestimation of COPD morbidity and COPD or CHD mortality
risks but was not possible for COPD or CHD mortality risk in never smokers because there were
no events in the reference category of the comparison model. The overestimations of risk were
for COPD morbidity risk in never smokers (categories 8 and 9) and for COPD or CHD mortality
risk in individuals with a baseline age of 45 or younger (categories 6, 8, and 9) (Tables 4.3 and
4.4). Underestimation of morbidity and mortality risks could also have occurred through selfselection of healthier subjects into the Copenhagen City Heart Study and subjects lost to followup.
As COPD morbidity is generally underdiagnosed and mortality underreported, misclassification
could have biased the results toward the null and decreased associations.84 Thus, the COPD or
CHD mortality outcome was used.60, 61, 102 COPD morbidity defined as a hospital diagnosis limits
the generalizability of the results to individuals with more severe disease. The FEV1 slope
calculated from only two measurements is vulnerable to measurement error, although use of
quartiles may have lessened this effect. Also, individuals with abnormal baseline lung function
were included in the models. Overall Cox models were conducted post hoc excluding: 1)
individuals with a ratio of FEV1b/FVCb below the LLN and then 2) individuals with FEV1b and
FEV1b/FVCb below the LLN. These results differed mainly by lower HRs in category 9.
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In conclusion, this study demonstrates the usefulness of a combined cross-sectional and
longitudinal evaluation of FEV1 in an aging, community-based cohort. Combinations of
decreasing baseline FEV1 and increasing FEV1 slope showed steadily increasing trends in
morbidity and mortality risks. The combined approach may provide more useful information for
early identification of disease, even in individuals with a ‘normal’ FEV1. These study results may
be useful to health care providers who evaluate patients at risk for lung function decline.
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Examination 1
1976–78

Examination 2
1981–83

13,830 Subjects

12,354 Subjects

End of Follow-up
2006
2009

1,405 COPD Morbidity

Study cohort: Spirometry at examinations
10,457 Subjects

1,915 COPD or CHD Mortality

one and two

6,666 All-cause Mortality

Figure 4.1 Sample size and morbidity and mortality follow-up. Above the timeline are the numbers of subjects who participated in spirometry testing by Copenhagen
City Heart Study examination. Below the timeline is the number of subjects who participated in spirometry testing at examinat ions one and two and the numbers of
health outcomes that occurred during the morbidity and mortality follow-up periods. Note that the follow-up periods are represented as dashed lines and that followup for COPD or CHD mortality ended in 2006.
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Study Cohort

Baseline FEV 1
in Comparison
to Predicted

Category by
Quartile of
FEV1 Slope
1. Quartile 1
(n = 328)
reference
2. Quartile 2
(n = 720)

FEV1b ≥
Predicted
3. Quartile 3
(n = 812)

4. Quartile 4
(n = 1,201)
Spirometry at
examinations
one and two
(n = 10,457)

5. Quartile 1
(n = 1,172)

FEV1b <
Predicted
and ≥ LLN

9. FEV1b < LLN
(n = 1,915)

6. Quartile 2
(n = 1,765)

7. Quartile 3
(n = 1,409)

8. Quartile 4
(n = 1,135)

Figure 4.2 Nine lung function categories based on baseline FEV1 values in comparison to predicted values and quartiles of FEV1
slope. European reference equations were used to calculate the predicted FEV 1 values.111 FEV1b, baseline forced expiratory volume
in one second; LLN, lower limit of normal.
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Table 4.1 Characteristics of the subcohorts for the Cox proportional hazards model analysis
Males

Females

Never smokers

Subjects present for examinations one and two*
Subjects (n, %)†
Baseline age (mean, SD)

4,598

44.0

5,859

56.0

1,949

18.6

52.2

11.6

52.4

11.0

52.3

12.4

Subjects with baseline age ≤ 45 (mean, SD)

37.5

6.0

37.6

5.9

36.4

6.4

Subjects with baseline age > 45 (mean, SD)

57.8

7.5

57.4

7.2

58.8

7.5

COPD morbidity

17.0

8.8

19.6

7.9

21.1

7.7

COPD or CHD mortality

16.7

7.9

19.2

6.9

20.1

6.7

All-cause mortality

17.5

8.7

20.2

7.8

Years of follow-up (mean, SD)

FEV1b, l (mean, SD)
FEV1b, % predicted (mean, SD)

3.09
88.6

0.83
18.2

2.25
91.9

0.55
17.8

7.6
0.85; 0.55‡

95.0; 96.6‡

15.9; 18.0‡

FEV1b ≥ predicted (n, %)

1,189

25.9

1,872

Q1 Slope FEV1 (n, %)

170

14.3

158

8.4

78

9.9

Q2 Slope FEV1 (n, %)

253

21.3

467

24.9

179

22.6

Q3 Slope FEV1 (n, %)

317

26.7

495

26.4

212

26.8

Q4 Slope FEV1 (n, %)

449

37.8

752

40.2

322

40.7

FEV1b < predicted and ≥ LLN (n, %)

32.0

21.3
3.48; 2.31‡
791

40.6

2,420

52.6

3,061

52.2

962

49.4

Q1 Slope FEV1 (n, %)

528

21.8

644

21.0

241

25.1

Q2 Slope FEV1 (n, %)

735

30.4

1,030

33.6

320

33.3

Q3 Slope FEV1 (n, %)

606

25.0

803

26.2

248

25.8

Q4 Slope FEV1 (n, %)

15.9

551

22.8

584

19.1

153

FEV1b < LLN (n, %)

989

21.5

926

15.8

196

10.1

Slope FEV1, ml/yr (mean, SD)

–61

91

–44

69

–48; –40‡

95; 71‡

25th percentile
Median
th

75 percentile
Never smokers (n, %)§

–117

–94

–113; –81‡

–59

–55

–57; –39‡

0

0

–16; 0‡

453

9.9

1,496

25.5

Former smokers (n, %)§

1,210

26.3

1,224

20.9

Current smokers (n, %)§

2,922

63.5

3,082

52.6

453; 1,496‡

*Spirometry tests were 4 to 7 years apart from examination one to two with a mean follow-up of 5 years.
†A total of 10,457 subjects were present for examinations one and two.
‡Males; females.
§Ascertained at examination two.
FEV1b, baseline forced expiratory volume in one second; l, liters; LLN, lower limit of normal; ml/yr, milliliters/year; SD, standard deviation.
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23.2; 76.8‡

4.3a. COPD Morbidity

4.3b. COPD or CHD Mortality

4.3c All-cause Mortality

Figure 4.3. Cox proportional hazards model results for overall risks of (a) COPD morbidity, (b) COPD or CHD mortality, and c) allcause mortality by lung function category. Models adjusted for baseline age and height. FEV1b, baseline forced expiratory volume in
one second; LLN, lower limit of normal; pred., predicted value.
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Table 4.2 Population attributable risks (PAR) for morbidity and mortality in the
overall study cohort*
HR
95% CI
PAR (%)
COPD Morbidity

(n=10,383; COPD=1,405)

Categories 1–8

1.00

Category 9

4.35

Categories 1–7

1.00

Categories 8 and 9
COPD or CHD Mortality

4.42

37.6

(3.97–4.91)

49.6

(n=10,457; Deaths=1,915)

Categories 1–8

1.00

Category 9

2.48

Categories 1–7

1.00

Categories 8 and 9
All-cause Mortality

(3.90–4.85)

2.53

(2.24–2.74)

21.3

(2.31–2.78)

30.9

(n=10,457; Deaths=6,666)

Categories 1–8

1.00

Category 9

1.80

Categories 1–7

1.00

Categories 8 and 9

1.85

*Models adjusted for baseline age and height.

68

(1.70–1.91)

12.8

(1.75–1.95)

19.9

25%

20%

15%

10%

5%

0%
FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < LLN
and Q1 slope and Q2 slope and Q3 slope and Q4 slope and ≥ LLN and and ≥ LLN and and ≥ LLN and and ≥ LLN and
Q1 slope
Q2 slope
Q3 slope
Q4 slope

Figure 4.4 Overall prevalence rates of self-reported respiratory symptoms (chronic bronchitis = solid line; shortness of breath =
dashed line) at examination two by lung function category. FEV1b, baseline forced expiratory volume in one second; LLN, lower limit
of normal; pred., predicted value.
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Table 4.3 Cox proportional hazards models for morbidity and mortality risks by lung function category and subcohort*
Males
Females
HR

95% CI

HR

95% CI

Never Smokers
HR

95% CI

COPD Morbidity

(n=4,550; COPD=616)

(n=5,833; COPD=789)

FEV1b ≥ pred. and Q1 slope

1.00

1.00

FEV1b ≥ pred. and Q2 slope

0.68

(0.27–1.71)

1.15

(0.42–3.15)

0.27

(0.05–1.64)

FEV1b ≥ pred. and Q3 slope

1.18

(0.54–2.58)

1.52

(0.58–4.01)

0.12

(0.01–1.12)

FEV1b ≥ pred. and Q4 slope

1.38

(0.65–2.90)

2.99

(1.20–7.44)

0.68

(0.18–2.57)

FEV1b < pred. and ≥ LLN and Q1 slope

1.25

(0.60–2.60)

3.68

(1.48–9.15)

0.80

(0.21–3.10)

FEV1b < pred. and ≥ LLN and Q2 slope

1.85

(0.92–3.72)

4.90

(2.00–11.97)

1.15

(0.32–4.08)

FEV1b < pred. and ≥ LLN and Q3 slope

3.10

(1.56–6.17)

6.06

(2.47–14.86)

1.44

(0.41–5.11)

FEV1b < pred. and ≥ LLN and Q4 slope

5.11

(2.58–10.13)

11.63

(4.75–28.46)

3.09

(0.88–10.86)

FEV1b < LLN

9.38

(4.82–18.24)

18.05

(7.44–43.78)

3.44

(1.00–11.77)

COPD or CHD Mortality

(n=4,598; Deaths=1,053)

(n=1,943; COPD=75)
1.00

(n=5,859; Deaths=862)

1.00

FEV1b ≥ pred. and Q2 slope

1.33

(0.77–2.31)

1.93

(0.87–4.29)

2.33

(0.68–7.91)

FEV1b ≥ pred. and Q3 slope

1.23

(0.72–2.10)

2.19

(0.99–4.84)

2.39

(0.71–7.99)

FEV1b ≥ pred. and Q4 slope

1.43

(0.85–2.39)

3.04

(1.41–6.55)

2.10

(0.64–6.90)

FEV1b < pred. and ≥ LLN and Q1 slope

1.48

(0.90–2.45)

3.58

(1.65–7.75)

2.92

(0.88–9.61)

FEV1b < pred. and ≥ LLN and Q2 slope

1.53

(0.93–2.50)

3.46

(1.62–7.40)

3.18

(0.98–10.33)

FEV1b < pred. and ≥ LLN and Q3 slope

1.96

(1.20–3.20)

4.22

(1.97–9.05)

2.78

(0.84–9.19)

FEV1b < pred. and ≥ LLN and Q4 slope

3.03

(1.86–4.95)

7.47

(3.49–16.00)

4.90

(1.48–16.30)

3.71

(2.30–5.96)

11.11

(5.22–23.62)

4.50

(1.36–14.95)

FEV1b < LLN
All-cause Mortality

1.00

(n=1,949; Deaths=208)†

FEV1b ≥ pred. and Q1 slope

(n=4,598; Deaths=3,217)

1.00

(n=5,859; Deaths=3,449)
1.00

(n=1,949; Deaths=987)

FEV1b ≥ pred. and Q1 slope

1.00

FEV1b ≥ pred. and Q2 slope

1.03

(0.79–1.35)

1.05

(0.81–1.37)

1.00
1.05

(0.70–1.58)

FEV1b ≥ pred. and Q3 slope

0.93

(0.72–1.21)

1.16

(0.90–1.51)

1.12

(0.76–1.66)

FEV1b ≥ pred. and Q4 slope

1.12

(0.88–1.44)

1.34

(1.05–1.72)

1.22

(0.84–1.77)

FEV1b < pred. and ≥ LLN and Q1 slope

1.14

(0.90–1.45)

1.30

(1.01–1.68)

1.11

(0.75–1.64)

FEV1b < pred. and ≥ LLN and Q2 slope

1.34

(1.06–1.68)

1.55

(1.22–1.98)

1.38

(0.95–2.00)

FEV1b < pred. and ≥ LLN and Q3 slope

1.40

(1.11–1.77)

1.62

(1.26–2.07)

1.28

(0.88–1.88)

FEV1b < pred. and ≥ LLN and Q4 slope

2.01

(1.59–2.54)

2.40

(1.87–3.08)

1.89

(1.27–2.80)

FEV1b < LLN

2.24

(1.79–2.80)

2.85

(2.23–3.63)

1.66

(1.12–2.47)

*Adjusted for baseline age and height.
†Sensitivity analysis was not possible due to a lack of cases in the reference category after excluding the adjusted 1981 FEV1 values.
FEV1b, baseline forced expiratory volume in one second; LLN, lower limit of normal; pred., predicted value.
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Table 4.4 Cox proportional hazards models for morbidity and mortality risks by lung function category and baseline age*
Baseline Age ≤ 45
Baseline Age > 45
HR
COPD Morbidity

95% CI

(n=2,726; COPD=269)

HR

95% CI

(n=7,657; COPD=1,136)

FEV1b ≥ pred. and Q1 slope

1.00

FEV1b ≥ pred. and Q2 slope

0.75

(0.23–2.47)

0.91

(0.41–2.02)

FEV1b ≥ pred. and Q3 slope

1.19

(0.41–3.43)

1.35

(0.65–2.83)

FEV1b ≥ pred. and Q4 slope

1.69

(0.63–4.50)

2.15

(1.07–4.31)

FEV1b < pred. and ≥ LLN and Q1 slope

1.92

(0.74–4.97)

2.35

(1.17–4.71)

FEV1b < pred. and ≥ LLN and Q2 slope

2.66

(1.06–6.71)

3.29

(1.68–6.46)

FEV1b < pred. and ≥ LLN and Q3 slope

2.64

(1.03–6.76)

4.91

(2.51–9.60)

FEV1b < pred. and ≥ LLN and Q4 slope

4.79

(1.88–12.17)

8.48

(4.34–16.57)

FEV1b < LLN

6.21

(2.52–15.33)

15.26

(7.88–29.54)

COPD or CHD Mortality

1.00

(n=2,732; Deaths=136)

(n=7,725; Deaths=1,779)

FEV1b ≥ pred. and Q1 slope

1.00

FEV1b ≥ pred. and Q2 slope

1.12

(0.27–4.67)

1.41

(0.88–2.27)

FEV1b ≥ pred. and Q3 slope

1.69

(0.46–6.24)

1.47

(0.93–2.35)

FEV1b ≥ pred. and Q4 slope

0.86

(0.22–3.44)

1.87

(1.19–2.91)

FEV1b < pred. and ≥ LLN and Q1 slope

1.71

(0.49–5.90)

2.10

(1.35–3.28)

FEV1b < pred. and ≥ LLN and Q2 slope

2.67

(0.81–8.83)

1.98

(1.28–3.07)

FEV1b < pred. and ≥ LLN and Q3 slope

1.59

(0.45–5.64)

2.61

(1.69–4.03)

FEV1b < pred. and ≥ LLN and Q4 slope

3.77

(1.12–12.71)

4.09

(2.65–6.33)

FEV1b < LLN

4.39

(1.36–14.23)

5.46

(3.56–8.37)

All-cause Mortality

1.00

(n=2,732; Deaths=715)

(n=7,725; Deaths=5,951)

FEV1b ≥ pred. and Q1 slope

1.00

FEV1b ≥ pred. and Q2 slope

1.17

(0.66–2.08)

1.00
0.97

(0.80–1.19)

FEV1b ≥ pred. and Q3 slope

1.55

(0.90–2.66)

0.99

(0.82–1.21)

FEV1b ≥ pred. and Q4 slope

1.62

(0.96–2.72)

1.14

(0.95–1.37)

FEV1b < pred. and ≥ LLN and Q1 slope

1.69

(1.02–2.81)

1.15

(0.95–1.38)

FEV1b < pred. and ≥ LLN and Q2 slope

2.00

(1.22–3.29)

1.35

(1.13–1.61)

FEV1b < pred. and ≥ LLN and Q3 slope

1.81

(1.09–3.02)

1.42

(1.19–1.70)

FEV1b < pred. and ≥ LLN and Q4 slope

2.66

(1.60–4.43)

2.06

(1.72–2.47)

FEV1b < LLN

3.21

(1.98–5.23)

2.35

(1.97–2.80)

*Models adjusted for baseline age and height.
FEV1b, baseline forced expiratory volume in one second; LLN, lower limit of normal; pred., predicted value.
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Figure 4.5 Cumulative incidence by lung function category, for three subcohorts (■ = males; ● = females; ▲ = never smokers) and
three outcomes (COPD morbidity = solid line; COPD or CHD mortality = dashed line; all-cause mortality = dash dot line). FEV1b,
baseline forced expiratory volume in one second; LLN, lower limit of normal; pred., predicted value.
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Chapter 5
5.1

Summary

Excessive lung function decline is an indicator of an underlying adverse health condition that
may lead to the development of COPD. The principal risk factor for COPD is tobacco smoking, a
highly-prevalent risk factor in the Copenhagen City Heart Study sample used for this study.69, 70
Accordingly, this was a fitting sample for the current study because a majority of subjects were
at risk for lung function decline. Previous literature on lung function decline has focused on
characterizing lung function decline as an independent risk factor for morbidity and mortality,
through the use of multivariate models adjusted for known risk factors.24-34, 39, 54-57 Although the
risk of mortality has been studied most often, these studies demonstrate that lung function
decline is a risk factor for morbidity and mortality. This earlier research provides the basis for
the current study, one that followed a different approach to investigate lung function as a
predictor of morbidity and mortality rather than as a causative factor among a multitude of other
risk factors.
Morbidity and mortality risks associated with lung function decline in minimally-adjusted
models are less often studied. However, there is a need to understand the relationships between
the outcome of lung function decline with morbidity and mortality to help inform prevention
activities that are based on observed lung function decline. Although longitudinal spirometry is
conducted in clinical and occupational settings, the evaluation of the rate of decline in
individuals in prospectively collected spirometry data is a subject of current research,5, 6
including such topics as how soon one can make sound decisions for prevention and intervention
based upon these data. This study helped to address questions about the usefulness of periodic
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spirometry and screening criteria to make optimal use of periodic spirometry for disease
prevention and intervention measures.
Specifically, the goal of this study was to evaluate the epidemiologic nature and utility of
longitudinal measurements of FEV1 as predictors for COPD, COPD or CHD mortality, and allcause mortality in an aging, population-based sample. The results of this evaluation were
intended to be applicable to community and workplace screening of at-risk individuals for
respiratory disease and in the secondary prevention of disease. By design, the minimally-adjusted
models were intended to maximize the observed effects of the respiratory health status outcomes
(lung function level and rate of decline, respiratory symptoms, and asthma) on morbidity and
mortality risks, as each can be used as indicators for prevention purposes. Inclusion of other
possible risk factors, which often contribute to these respiratory health status outcomes, would
have partially accounted for the effects of these outcomes and detracted from our study‟s purpose
and the relationships of interest.
Three related studies accomplished various objectives related to the overall goal of this project.
The first study addressed questions pertaining to methods used in occupational respiratory health
monitoring programs, namely the value of longitudinal spirometry data as compared to selfreported respiratory symptom questionnaire data, and various representations and methods of
assessing longitudinal spirometry data.51, 52 The second study benefited from the agestratification of the sample, by examining morbidity and mortality risks among individuals below
ages when spirometry is recommended and COPD typically becomes apparent.88, 89 The second
study also benefited from the necessary mid-study change in model of spirometer, investigating
risks associated with patterns of decline created from the two periods. Building upon the
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observed associations between the level of lung function and the rate of decline with morbidity
and mortality risks in the first two studies, a novel and more direct assessment was made with the
combination of the level and the rate of decline as a predictor of morbidity and mortality.
Results from the first study demonstrated the predictive capacities of four criteria for lung
function decline potentially usable in practice.51, 52 Among the quartile-based criteria, higher
morbidity and mortality risks were associated with the slope than with the relative slope. As for
the two limits of longitudinal decline, higher morbidity and mortality risks were associated with
the ACOEM LNL than with the 90 ml/yr limit. In general, associations were strongest with
COPD morbidity outcomes. Associations with COPD or CHD mortality were slightly higher
than with all-cause mortality. Females were at greater risk than males across all measures of lung
function decline, as found in the literature.75 With lower tobacco consumption than males, this
may indicate higher susceptibility in females.76, 77 Never smokers had increasing trends overall,
but their trends were less often statistically significant.
Critical rates of decline associated with increased morbidity risk were observed at the third
quartiles of the slope (declines starting at 60 ml/yr for males and 57 ml/yr for females) with risks
greater than 2.5 times those for the reference. For mortality, the fourth quartiles of the slope
(declines starting at 118 ml/yr for males and 95 ml/yr for females) nearly doubled COPD or
CHD mortality risks for males and tripled them for females. Respective risks for all-cause
mortality increased by 67% and 88%. Similarities exist with community-based and occupational
studies of lung function decline and respiratory morbidity and mortality,29, 33, 36, 57, 68 including
slightly higher risks in females as compared to males for COPD hospitalization and all-cause
mortality29, 33 and increased risk of cardiac mortality in males.57 Similarities were also found in a
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study of underground coal miners with a two-fold cardiovascular and nonmalignant respiratory
disease mortality risk,36 and statistically significant declines above 90 ml/yr for mortality as were
declines of 60 ml/yr or more for never smokers.68
Lung function decline demonstrated often greater risks than respiratory symptoms and asthma,
but their risks remained statistically significant in multivariate models with lung function.
Reported respiratory symptoms (chronic bronchitis, cough, phlegm, and shortness of breath) and
asthma have been associated with increased morbidity and mortality risks,78-82 even after
controlling for FEV1.83 In contrast, the current study did not identify increased risk between
asthma and respiratory mortality, but this may be due to our specific focus on COPD.78
Additionally, chronic bronchitis was often a significant mortality predictor in our study, even
after adjustment for shortness of breath and height-adjusted baseline lung function.83
In the second study‟s reassessment of critical cut-points where lung function decline was
associated with increased morbidity and mortality risks using spirometry data from the last two
examinations and extended outcome follow-up, the results were generally consistent with our
previous assessment from examinations one and two, despite the adjustment to the 1981 FEV1
values in the first study and possible influences of improvements in spirometry standards. High
COPD morbidity and mortality risks were again associated with lower lung function levels and
excessive decline. Morbidity and mortality risks increased starting at –77 and –54 ml/yr in males
and –57 and –41 ml/yr in females, respectively. A cut-point in the FEV1 slope of –49 ml/yr was
associated with the start of increased morbidity and mortality risks in the overall cohort. General
similarities to previous studies include significant associations between lung function decline and
COPD hospitalizations and mortality, with some studies reporting higher associations for
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females than for males.27-29, 33 Again, FEV1 slope cut-points demonstrating increased mortality
risks in males were similar to those for underground coal miners, risks that increased at –60
ml/yr and were statistically significant at –90 ml/yr.68
For individuals with a baseline age of 45 years or younger, excessive decline was a significant
predictor of morbidity and mortality. These results are relevant to screening practices as
spirometry testing is currently recommended for individuals age 45 or older with other risk
factors.88, 89 Further, considering gender and age, morbidity and mortality risks were higher
among females, even with lower rates of smoking in younger females.76, 77 As for symptoms,
chronic bronchitis was a significant predictor of morbidity in younger individuals, as in the
Framingham Offspring cohort.96 Given these results for younger individuals, and that low lung
function in young, non-asthmatic adults predicts airflow obstruction at middle age,97 screening at
earlier ages in at-risk populations (e.g., smokers, symptomatic individuals, occupationallyexposed groups) may be useful. Additional evidence for early screening resulted from the
estimation of risks associated with early, late, and persistent patterns of lung function decline,
where increasing morbidity and mortality risks were observed with increasing persistence of
excessive decline and respiratory symptoms in males and females. Never smokers had a two-fold
mortality risk with persistent excessive decline. Screening for early declines as these occurring
over 4–7 years followed by intervention could help prevent the even greater risks observed with
late or persistent declines.
The novel approach offered by the third study in the estimation of morbidity and mortality risks
associated with lung function, whereby categories were created from the level and rate of lung
function decline, showed one central and important finding. An excessive rate of decline is
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associated with increased morbidity and mortality risks, even with a ‘normal’ baseline level of
lung function. Increasing trends in risk were consistently identified with baseline FEV1 at or
above the LLN and increasing quartiles of decline across males, females, never smokers, and
with a baseline age above and below 45. Further, population attributable risks112 for an abnormal
FEV1 (below the LLN), and then jointly with the category of a ‘normal’ FEV1 and the steepest
declines demonstrated substantial additional contributions, indicating that accelerated FEV1
decline in those with ‘normal’ FEV1 is of public health significance and concern. Broad
similarities to prior studies were higher morbidity and mortality risks among females,29, 33 which
may result from increased susceptibility to the effects of smoking,77 and increased COPD
morbidity risks with lower lung function at younger ages.96
However, chronic inflammatory processes in the lungs that lead to elastic tissue loss and small
airways remodeling with COPD105 progress over many years before disease can be detected. This
inflammation in the lungs may also contribute to systemic inflammation and non-pulmonary
disease.108 The consequences of a single abnormal spirometry test result differs for individuals,
with some following a normal age trajectory, and others with normal results can have excessive
decline. Early COPD detection may be improved through longitudinal spirometry testing in atrisk populations.21,98 Well-established risk factors for excessive decline are similar to those for
COPD.1, 33, 34, 96 Longitudinal spirometry may identify those individuals who have a high level of
lung function but excessive decline, whose disease could progress undetected leading to
increased morbidity and mortality risks.51, 109
In summary, although it is well-know that utilization of longitudinal spirometry data is often
complex due to issues of data standardization and quality, and effective interpretation of
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results,109 solutions have been offered to help overcome these challenges.113, 114 This study
acknowledges these challenges. Nonetheless, it also offers new knowledge to help advance
research on lung function decline related to prevention of lung function decline, intervention on
excessive lung function decline, secondary disease prevention, and reduction of premature
mortality.
5.2

Significance

The goal of this study was to evaluate the epidemiologic nature and utility of longitudinal lung
function measurements as predictors for COPD, COPD or CHD mortality, and all-cause
mortality in minimally-adjusted models using an at-risk, aging, population-based sample for the
purposes of improving disease prevention. The significance of this study lies not only in the
estimation of the morbidity and mortality risks from a long outcome follow-up, but also in the
applicability of the results for prevention. The first study compared multiple measures of
longitudinal lung function decline (FEV1 slope, FEV1 relative slope, ACOEM LNL, and a 90
ml/yr limit), adjusted for respiratory symptoms and asthma, as predictors of morbidity and
mortality. The logic behind these models was correspondence to data resulting from occupational
respiratory monitoring programs and to demonstrate the relative value of the longitudinal
measures and respiratory symptoms and asthma, and also the relative value of longitudinal and
cross-sectional evaluation of spirometry data. The second study focused mainly on estimating
risks for individuals younger than the recommended age for spirometry testing107 and for patterns
of early, late, and persistent lung function decline. The message of this study was that earlier
intervention may be beneficial in preventing the incidence of COPD morbidity and premature
mortality. The third study involved a novel method of combining the level of lung function and
the rate of decline to study their combined effect as a predictor of morbidity and mortality. These
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results may be very important. Significantly increased morbidity and mortality risks were
observed for individuals with a normal level of lung function and a steep decline, demonstrating
that use of only a cross-sectional comparison of the lung function level to a reference population
to determine normality would fail to identify a number of individuals at increased risk for
morbidity and mortality.
The significance of this study is relevant to healthcare practitioners, including both primary care
practitioners with regard to recognition of persistent symptoms or exposures in patients, uses of
spirometry, and timely referral for specialized care; and specialized care providers where the
extent of the problem is determined with spirometry and a range of the patients are treated, from
individuals with early signs of disease to those whose existing disease is managed and monitored
for progression. This study is also relevant to workplace prevention where respiratory health
screening and monitoring are conducted due to potentially hazardous exposures, and to public
health through three broad Healthy People 2020 Respiratory Disease, COPD objectives: RD-10
(Reduce deaths from COPD among adults.), RD-11 (Reduce hospitalizations for COPD.), and
RD-13 ([Developmental] Increase the proportion of adults with abnormal lung function whose
underlying obstructive disease has been diagnosed.).49
5.3

Strengths and Limitations

The use of a large, age-stratified, population-based sample with a prospective study design and
long outcome follow-up demonstrate significant strengths in the three studies. The high
prevalence rates of smoking provided an excellent sample in which to study morbidity and
mortality risks associated with lung function decline. Given that this is an at-risk sample, the
findings are relevant to both clinical and workplace disease prevention and cost-reduction.66, 67
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There are several limitations shared by the three studies. As described in the first study,
preliminary analysis of mean FEV1 values by year of examination revealed a slightly excessive
increase in mean FEV1 in 1981 (n = 4,319), but not in 1982 (n = 5,353) or 1983 (n = 2,593), as
compared to mean FEV1 at the baseline examinations in 1976–78. An a priori decision was made
to devise a method of adjustment using a mean value, a generally statistically reasonable
approach, in order to adjust and retain the 1981 data. The decision to adjust rather than to
exclude the 1981 values was based on the potential loss of subjects and a reduction in power if
these data were excluded. More importantly, we suspected COPD morbidity outcomes would be
few in number for never smokers. Sensitivity analyses were conducted to assess the effect of the
adjustment on the results from models that used the adjusted data values, whereby the Cox
models were conducted on samples excluding the adjusted 1981 values (Appendices A-C).
Results of the sensitivity analysis for the first study indicated that the risks did not appear to be
overestimated in the models with the adjusted data. The inclusion of the adjusted data resulted in
an underestimation of the COPD morbidity risks for the level of lung function, the slope, and the
relative slope and mainly so for never smokers and more often for females than for males as well
as underestimation of COPD or CHD mortality risk for the level of lung function for never
smokers. In the second study, the adjustment appeared to have resulted in an underestimation of
risks, including the fourth quartiles of the slope for COPD morbidity risk in males over age 45
and for COPD or CHD mortality risk in females age 45 years and younger, and with a persistent
pattern of decline in the slope for COPD morbidity risk in males. For the third study, sensitivity
analyses indicated under- and overestimation of COPD morbidity and COPD or CHD mortality
risks, where overestimation was found for COPD morbidity risk in never smokers and COPD or
CHD mortality risk in individuals with a baseline age of 45 years and younger.
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The spirometry measurements were collected across a 28-year span. However, the necessary
change in the model of spirometer after examination two, due to mechanical failure,98 prevented
estimation of morbidity and mortality risks associated with lung function decline across the
entire study period. Thus, only two spirometry measurements were used to calculate the rate of
change in FEV1, creating a vulnerability to measurement error, but the use of quartile groupings
was used to address this bias and could have reduced this effect, if the error was not excessive.
These studies were not designed to account for possible mixing between cause and effect with
regard to steeply declining lung function and COPD outcomes. Nor did they adjust for many
possible confounders. The research question was purely in the relationships of lung function
decline with morbidity and mortality for prevention purposes rather than causation. For example,
individuals with abnormal baseline lung function were included in the models for the third study,
but post hoc analyses excluding these individuals showed little difference from the results of the
original models. Lung function decline was a significant predictor of morbidity and mortality in
either scenario.
The 90 ml/yr limit of decline used in the first study was from research on males.52 This limit was
used for females as well, because no corresponding limit was found in the literature for females.
Even though females generally have smaller lungs,75 in this at-risk population, the 90 ml/yr limit
was appropriate as it was similar to the fourth quartile of the slope in females, starting at 95
ml/yr.
Two possible sources of bias in the outcomes are underdiagnosis of COPD and underreporting of
COPD as a cause of death. These could have resulted in misclassification, biasing the results
toward the null and decreasing the associations.84 This potential bias was addressed by
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combining the often interrelated COPD and CHD mortality into one cardiopulmonary mortality
outcome.60, 61, 102 Also, as COPD morbidity was defined with a hospital diagnosis, our results
generally represent risks for individuals with more severe disease. Generalizability of the results
may be limited to individuals with more severe disease, but also likely the individuals
representing the highest costs and in need of the most care.
Other possible selection bias includes subjects lost to follow-up who were older at baseline, had
a lower lung function level, and a higher proportion of self-reported current asthma, respiratory
symptoms, and smoking as compared those who were included in the studies due to participation
and spirometry testing at examinations one and two and/or examinations three and four. This
bias could have caused an underestimation of risk, particularly in the second study with the
estimation of risks associated with patterns of lung function decline using participants attending
all four examinations. Risks of morbidity and mortality could also have been underestimated due
to self-selection of healthier subjects into the Copenhagen City Heart Study.
5.4

Future Research

The findings of this study identify the need for further investigation of gender differences in
morbidity and mortality risks associated with the level and rate of lung function decline and
respiratory symptoms and asthma. Gender differences related to COPD are not fully clear or
understood.77, 115 Additional measures of lung function could be considered in future research.
This study focused upon FEV1 as it has been identified as the best lung function measurement to
estimate the rate of decline,71 but recent research has reconsidered the value of FEV1 in
comparison to FVC and the ratio of FEV1/FVC in predicting survival.116 Additional analyses
could be conducted using these two alternative measures to determine their value for prevention
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purposes in the context of the models investigated in this study. Other population-based data sets,
such as the NHANES, could be used to assess whether the results of this study could be
replicated or expanded upon using other populations. Finally, understanding the practical value
and applicability of this research, closing a gap between research and practice, is of utmost
importance. As there are barriers to the implementation of longitudinal spirometry such as cost,
data standardization and quality, and effective interpretation of results,109 studies could be
conducted pertaining to the feasibility, performance, and individual benefit of implementing
longitudinal spirometry in healthcare and occupational settings, including evaluation of new and
existing programs.
5.5

Conclusion

The findings of this study extend knowledge on lung function as a predictor of adverse health
outcomes in an aging population, the need for early identification and prevention of lung
function decline, and the possibilities to decrease associated risks for COPD morbidity and
premature mortality in individuals who have significant exposures to known risk factors for lung
function decline or the development of COPD. The results of this study build upon previous
findings of lung function decline as a risk factor for adverse outcomes. They also add to our
understanding of the epidemiologic nature and utility of lung function decline as a predictor.
Results especially pertinent to workplace respiratory monitoring programs are that the level and
rate of lung function decline generally demonstrated higher morbidity and mortality risks than
respiratory symptoms and asthma. Comparison of the risks associated with the level and rate of
lung function decline provided further evidence that evaluation of lung function decline is
important in disease prevention.
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From a clinical and public health perspective, associations between lung function decline and
increased morbidity and mortality risks in individuals at younger ages provided evidence that
lung function testing before middle age may be a worthwhile investment. This could represent
opportunities for early intervention and preservation of lung function. The risks associated with
early, late, and persistent patterns of lung function decline lend further support that early
detection of lung function decline coupled with appropriate intervention may reduce morbidity
and mortality risks.
Estimates of the combined effect of the level of lung function and the rate of lung function
decline as a predictor of morbidity and mortality further demonstrated that a combined approach
to lung function assessment may provide more useful information for prevention and early
identification of disease. This analysis also revealed the importance of monitoring for lung
function decline even in individuals with a ‘normal’ level of lung function. The findings suggest
that not only is lung function decline an important predictor of morbidity and mortality, but also
that early monitoring may be beneficial in reducing the burden of COPD morbidity and mortality
and premature mortality. Future research using other population-based studies may further
elucidate the relationship of lung function decline with morbidity and mortality and how to
translate results into practical applications that improve the effectiveness of spirometry
monitoring and risk reduction in clinical and occupational settings.
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6Appendix A: Sensitivity Analyses for Study 1
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Examination 1
1976–78

Examination 2
1982–83

13,826 Subjects

7,895 Subjects

Study cohort:
6,213 Subjects

End of Follow-up
2003 2006 2007

647 COPD Morbidity

Spirometry and ascertainment
of asthma, chronic bronchitis,
and shortness of breath

1,132 COPD or CHD Mortality
3,701 All-cause Mortality

Figure A.1 Sample size and morbidity and mortality follow-up. Above the timeline are the numbers of subjects who participated in spirometr y testing by Copenhagen
City Heart Study examination. Below the timeline is the number of subjects who participated in spirometry testing at examinat ions one and two and the numbers of
health outcomes that occurred during the morbidity and mortality follow-up periods. Note that the follow-up periods are represented as dashed lines. COPD morbidity
follow-up lasted until 2003. COPD or CHD mortality follow-up lasted until 2006. All-cause mortality follow-up lasted until 2007.
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Table A.1 Characteristics of the subcohorts for Cox proportional hazards model analysis using data for lung function level and decline
Data for lung function level
Males
Females

Never smokers

(Examination two)
Subjects (n, %)*
Age at examination two (mean, SD†)

3,542

44.6

4,404

55.4

1,669

21.0

56.3

12.5

56.7

12.0

56.5

13.7

COPD morbidity

14.9

7.0

17.0

6.0

17.9

5.6

COPD or CHD mortality

16.7

7.8

19.0

6.8

19.8

6.5

All-cause mortality

16.9

8.0

19.3

7.0

20.2

6.7

Follow-up, years (mean, SD)

Height, cm† (mean, SD)

174

7

161

6

165

9

FEV1, l† (mean, SD)

2.78

0.87

2.01

0.60

2.37

0.83

FEV1/height2 x mean height2, l (mean, SD)

2.54

0.72

2.13

0.58

2.39

0.66

25th percentile

2.07

1.76

2.40; 1.87‡

Median

2.55

2.12

2.90; 2.20‡

75th percentile

3.03

2.51

3.36; 2.60‡

Asthma (n, %)

113

3.2

152

3.5

35

2.1

Chronic bronchitis (n, %)

570

16.1

491

11.2

99

5.9

Shortness of breath (n, %)

349

9.9

483

11.0

103

6.2

Never smokers (n, %)

424

12.0

1,245

28.3

Former smokers (n, %)

880

24.8

788

17.9

Current smokers (n, %)

2,237

63.2

2,366

53.7

2,716

43.7

3,497

56.3

424; 1,245‡

25.4; 74.6‡

1,172

18.9

Data for lung function decline
(Examination one to two)§
Subjects (n,* %)
Baseline age (mean, SD)

52.7

11.4

52.7

10.9

52.9

12.2

COPD morbidity

15.0

6.8

17.1

5.8

18.0

5.4

COPD or CHD mortality

16.7

8.0

19.0

6.8

19.9

6.5

All-cause mortality

16.5

7.8

19.3

7.0

20.2

Follow-up, years (mean, SD)

6.7

Baseline FEV1, l (mean, SD)

3.09

0.82

2.24

0.56

2.57

0.80

Baseline FEV1/height2 x mean height2, l (mean, SD)

2.83

0.67

2.39

0.54

2.62

0.63

Slope FEV1, ml/yr† (mean, SD)
25th percentile

–69

91

–51

66

–50

–132

–95

–116; –95‡

Median

–76

–57

–58; –57‡

75th percentile

–19

–19

0; 0‡

Slope FEV1/baseline FEV1, %/yr (mean, SD)

–2.2

3.3

–2.2

3.2

–1.8

25th percentile

–4.1

–4.2

–3.5; –3.9‡

Median

–2.4

–2.4

–1.7; –2.2‡

75th percentile

–0.6

–0.7

0.0; 0.0‡

FEV1 below LNL† (n, %)

77

3.3

442

16.3

593

17.0

239

20.4

1,174

43.2

1,021

29.2

358

30.6

Asthma (n, %)

80

3.0

120

3.4

25

2.1

Chronic bronchitis (n, %)

434

16.0

380

10.9

64

5.5

Shortness of breath (n, %)

257

9.5

361

10.3

68

5.8

FEV1 decline of 90 ml/yr or more

*A total of 7,946 subjects were present for examination two and 6,213 subjects were present for examinations one and two.
†SD (standard deviation), cm (centimeters), l (liters), ml/yr (milliliters/year), and LNL (Longitudinal Normal Limit).
‡Males; females.
§Includes subjects with approximately five years between spirometry tests.
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Table A.2 Cox proportional hazards models for COPD morbidity (hospital diagnosis of COPD [ICD-8 491–492, ICD-10 J41–J44])
Males
Females
Data for lung function level*
(Examination two)

(n = 3,506; COPD = 378)
HR

95% CI

(n = 4,376; COPD = 458)
HR

Never smokers
(n = 1,665; COPD = 54)

95% CI

HR

95% CI

Q1 FEV1/height2

1.00

Q2 FEV1/height2

2.95

(1.73–5.04)

2.48

(1.56–3.93)

2.12

Q3 FEV1/height2

6.71

(3.99–11.27)

5.86

(3.77–9.12)

2.33

(0.60–9.10)

Q4 FEV1/height2

17.24

(10.21–29.13)

17.24

(11.10–26.76)

6.36

(1.71–23.66)

Asthma†

2.03

(1.44–2.85)

1.32

(0.95–1.85)

4.13

(1.67–10.17)

Chronic bronchitis†

2.11

(1.67–2.67)

2.32

(1.86–2.89)

3.52

(1.78–6.99)

2.55

(1.95–3.33)

2.58

(2.04–3.27)

2.36

(1.08–5.15)

Shortness of breath†
Data for lung function decline‡
(Examination one to two)

1.00

(n = 2,683; COPD = 289)
HR

95% CI

1.00

(n = 3,448; COPD = 356)
HR

(n = 1,162; COPD = 37)

95% CI

1.00

(0.54–8.32)

HR

95% CI

Q1 FEV1 slope

1.00

1.00

Q2 FEV1 slope

1.69

(1.16–2.46)

2.79

(1.98–3.92)

3.44

(0.94–12.60)

Q3 FEV1 slope

2.49

(1.75–3.54)

3.62

(2.55–5.13)

6.71

(1.80–24.97)

Q4 FEV1 slope

4.13

(2.83–6.03)

7.07

(4.97–10.06)

5.46

(1.31–22.74)

Asthma

1.30

(0.86–1.96)

0.85

(0.57–1.27)

4.60

(1.23–17.28)

Chronic bronchitis

1.79

(1.36–2.36)

2.30

(1.78–2.99)

3.52

(1.35–9.22)

Shortness of breath

2.32

(1.69–3.19)

1.90

(1.42–2.54)

0.65

(0.17–2.51)

Q1 FEV1 relative slope

1.00

Q2 FEV1 relative slope

1.65

(1.12–2.45)

2.42

(1.68–3.48)

3.05

(0.81–11.46)

Q3 FEV1 relative slope

2.28

(1.55–3.33)

2.97

(2.06–4.28)

6.11

(1.62–23.09)

Q4 FEV1 relative slope

3.46

(2.44–4.92)

6.01

(4.31–8.39)

6.80

(1.77–26.20)

Asthma

1.24

(0.81–1.89)

0.91

(0.61–1.37)

4.84

(1.28–18.34)

Chronic bronchitis

1.80

(1.37–2.36)

2.34

(1.80–3.03)

3.58

(1.37–9.37)

Shortness of breath

2.36

(1.72–3.24)

1.86

(1.39–2.49)

0.63

(0.16–2.47)

FEV1 below LNL

2.26

(1.72–2.96)

3.16

(2.49–4.02)

2.01

(0.94–4.32)

Asthma

1.41

(0.93–2.14)

0.87

(0.58–1.31)

4.89

(1.41–16.94)

Chronic bronchitis

1.89

(1.43–2.48)

2.56

(1.99–3.31)

3.39

(1.32–8.68)

Shortness of breath

2.48

(1.80–3.42)

2.04

(1.53–2.72)

0.81

(0.22–2.91)

FEV1 decline of 90 ml/yr or more

1.97

(1.54–2.52)

2.97

(2.34–3.76)

1.87

(0.88–3.98)

Asthma

1.38

(0.91–2.09)

0.89

(0.59–1.34)

4.78

(1.37–16.69)

Chronic bronchitis

1.91

(1.46–2.51)

2.51

(1.94–3.24)

3.37

(1.31–8.67)

Shortness of breath

2.59

(1.89–3.56)

2.18

(1.64–2.90)

0.82

(0.23–2.97)

1.00

1.00

*Models adjusted for age at examination two.
†Asthma, chronic bronchitis, and shortness of breath represented as dichotomous variables in all models.
‡Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2), and height. See Table A.1 for quartile values.
FEV1 relative slope, slope FEV1/baseline FEV1; LNL, Longitudinal Normal Limit.
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Table A.3 Cox proportional hazards models for COPD (ICD-8 491–492, ICD-10 J41–J44) or CHD mortality (ICD-8 410–414, and ICD-10 I20–I25)
Males
Females
Never smokers
Data for lung function level*
(Examination two)

(n = 3,542; Deaths = 766)
HR

95% CI

(n = 4,404; Deaths = 651)
HR

(n = 1,669; Deaths = 174)

95% CI

HR

95% CI

Q1 FEV1/height2

1.00

Q2 FEV1/height2

1.56

(1.13–2.15)

1.79

(1.21–2.65)

3.70

(1.28–10.73)

Q3 FEV1/height2

2.40

(1.76–3.28)

2.72

(1.87–3.97)

4.42

(1.56–12.48)

Q4 FEV1/height2

3.46

(2.52–4.76)

5.73

(3.95–8.33)

7.41

(2.63–20.86)

Asthma†

1.01

(0.73–1.38)

1.03

(0.74–1.43)

1.17

(0.47–2.91)

Chronic bronchitis†

1.34

(1.11–1.60)

1.72

(1.41–2.11)

1.53

(0.94–2.48)

2.40

(1.96–2.95)

2.27

(1.85–2.80)

1.43

(0.85–2.38)

Shortness of breath†
Data for lung function decline‡
(Examination one to two)

1.00

(n = 2,716; Deaths = 613)
HR

95% CI

1.00

(n = 3,497; Deaths = 519)
HR

(n = 1,172; Deaths = 125)

95% CI

1.00

HR

95% CI

Q1 FEV1 slope

1.00

Q2 FEV1 slope

1.10

(0.86–1.39)

1.58

(1.21–2.06)

1.00
1.26

(0.74–2.16)

Q3 FEV1 slope

1.38

(1.10–1.74)

1.87

(1.42–2.46)

1.42

(0.80–2.51)

Q4 FEV1 slope

1.90

(1.49–2.44)

3.41

(2.59–4.49)

1.53

(0.83–2.84)

Asthma

0.77

(0.53–1.12)

0.81

(0.55–1.19)

1.33

(0.42–4.16)

Chronic bronchitis

1.33

(1.08–1.63)

1.62

(1.28–2.04)

1.69

(0.90–3.17)

Shortness of breath

2.25

(1.77–2.85)

1.74

(1.35–2.24)

0.85

(0.39–1.82)

Q1 FEV1 relative slope

1.00

Q2 FEV1 relative slope

1.10

(0.85–1.41)

1.73

(1.30–2.29)

1.25

(0.71–2.18)

Q3 FEV1 relative slope

1.39

(1.09–1.78)

1.27

(0.94–1.71)

1.15

(0.64–2.08)

Q4 FEV1 relative slope

1.77

(1.40–2.22)

3.14

(2.43–4.05)

1.80

(1.03–3.15)

Asthma

0.77

(0.53–1.12)

0.74

(0.50–1.09)

1.32

(0.42–4.16)

Chronic bronchitis

1.32

(1.07–1.61)

1.68

(1.33–2.12)

1.67

(0.89–3.12)

Shortness of breath

2.25

(1.77–2.85)

1.71

(1.33–2.21)

0.82

(0.38–1.75)

FEV1 below LNL

1.60

(1.32–1.94)

2.31

(1.90–2.81)

1.21

(0.79–1.87)

Asthma

0.79

(0.54–1.15)

0.75

(0.51–1.11)

1.30

(0.42–4.04)

Chronic bronchitis

1.35

(1.10–1.65)

1.72

(1.37–2.16)

1.64

(0.88–3.07)

Shortness of breath

2.25

(1.78–2.86)

1.72

(1.34–2.22)

0.87

(0.41–1.86)

FEV1 decline of 90 ml/yr or more

1.56

(1.32–1.84)

2.31

(1.91–2.81)

1.54

(1.02–2.34)

Asthma

0.78

(0.53–1.14)

0.83

(0.57–1.23)

1.34

(0.43–4.15)

Chronic bronchitis

1.33

(1.09–1.63)

1.69

(1.34–2.13)

1.64

(0.88–3.06)

Shortness of breath

2.33

(1.85–2.95)

1.79

(1.39–2.30)

0.84

(0.40–1.79)

1.00

1.00

*Models adjusted for age at examination two.
†Asthma, chronic bronchitis, and shortness of breath represented as dichotomous variables in all models.
‡Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2), and height. See Table A.1 for quartile values.
FEV1 relative slope, slope FEV1/baseline FEV1; LNL, Longitudinal Normal Limit.
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Table A.4 Cox proportional hazards models for all-cause mortality
Males
Data for lung function level*
(Examination two)

(n = 3,542; Deaths = 2,259)
HR

95% CI

Females

Never smokers

(n = 4,404; Deaths = 2,352)

(n = 1,669; Deaths = 766)

HR

95% CI

HR

95% CI

Q1 FEV1/height2

1.00

Q2 FEV1/height2

1.37

(1.17–1.60)

1.44

(1.23–1.70)

1.89

(1.37–2.62)

Q3 FEV1/height2

1.89

(1.61–2.21)

1.88

(1.60–2.20)

2.07

(1.51–2.85)

Q4 FEV1/height2

2.63

(2.23–3.10)

2.79

(2.37–3.28)

2.64

(1.91–3.65)

Asthma†

0.89

(0.71–1.11)

1.14

(0.92–1.40)

1.16

(0.72–1.87)

Chronic bronchitis†

1.24

(1.11–1.39)

1.38

(1.23–1.56)

1.34

(1.04–1.73)

1.66

(1.45–1.90)

1.43

(1.26–1.63)

1.27

(0.97–1.66)

Shortness of breath†
Data for lung function decline‡
(Examination one to two)

1.00

(n = 2,708; Deaths = 1,796)
HR

95% CI

1.00

(n = 3,486; Deaths = 1,863)
HR

(n = 1,165; Deaths = 543)

95% CI

1.00

HR

95% CI

Q1 FEV1 slope

1.00

1.00

Q2 FEV1 slope

1.19

(1.03–1.36)

1.23

(1.07–1.40)

1.21

(0.93–1.57)

Q3 FEV1 slope

1.26

(1.10–1.44)

1.34

(1.17–1.54)

1.20

(0.90–1.59)

Q4 FEV1 slope

1.76

(1.52–2.03)

1.88

(1.63–2.16)

1.71

(1.28–2.28)

Asthma

0.72

(0.55–0.94)

1.05

(0.82–1.33)

1.25

(0.72–2.18)

Chronic bronchitis

1.20

(1.06–1.36)

1.34

(1.17–1.54)

1.40

(1.01–1.94)

Shortness of breath

1.60

(1.36–1.87)

1.27

(1.09–1.48)

1.08

(0.77–1.52)

Q1 FEV1 relative slope

1.00

Q2 FEV1 relative slope

1.15

(0.99–1.32)

1.27

(1.10–1.45)

1.19

(0.91–1.55)

Q3 FEV1 relative slope

1.37

(1.19–1.57)

1.22

(1.06–1.41)

1.21

(0.92–1.60)

Q4 FEV1 relative slope

1.61

(1.40–1.84)

1.82

(1.59–2.07)

1.61

(1.23–2.12)

Asthma

0.72

(0.55–0.94)

1.01

(0.79–1.28)

1.29

(0.74–2.25)

Chronic bronchitis

1.19

(1.05–1.35)

1.37

(1.19–1.57)

1.40

(1.01–1.95)

Shortness of breath

1.61

(1.38–1.89)

1.26

(1.08–1.47)

1.06

(0.75–1.49)

FEV1 below LNL

1.48

(1.31–1.67)

1.61

(1.44–1.79)

1.27

(1.04–1.56)

Asthma

0.73

(0.56–0.96)

1.03

(0.81–1.30)

1.26

(0.72–2.18)

Chronic bronchitis

1.22

(1.07–1.38)

1.38

(1.20–1.58)

1.38

(1.00–1.92)

Shortness of breath

1.62

(1.38–1.90)

1.25

(1.07–1.46)

1.09

(0.77–1.53)

FEV1 decline of 90 ml/yr or more

1.37

(1.24–1.51)

1.56

(1.41–1.73)

1.38

(1.14–1.68)

Asthma

0.73

(0.56–0.95)

1.07

(0.85–1.37)

1.28

(0.74–2.21)

Chronic bronchitis

1.21

(1.07–1.37)

1.37

(1.19–1.57)

1.38

(1.00–1.92)

Shortness of breath

1.67

(1.43–1.96)

1.28

(1.09–1.49)

1.08

(0.77–1.52)

1.00

1.00

*Models adjusted for age at examination two.
†Asthma, chronic bronchitis, and shortness of breath represented as dichotomous variables in all models.
‡Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2), and height. See Table A.1 for quartile values.
FEV1 relative slope, slope FEV1/baseline FEV1; LNL, Longitudinal Normal Limit.
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A.2a. COPD Morbidity

A.2b. COPD or CHD Mortality

A.2c. All-cause Mortality

Figure A.2 Cox proportional hazards model results by gender (♦ = males and ● = females) for (a) COPD morbidity, (b) COPD or
CHD mortality, and (c) all-cause mortality. Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2),
height, and respiratory symptoms and asthma as dichotomous variables. Relative slope, FEV1/baseline FEV1; LNL, Longitudinal
Normal Limit. See Table A.1 for quartile values.
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A.3a. COPD Morbidity

A.3b. COPD or CHD Mortality

A.3c. All-cause Mortality

Figure A.3 Cox proportional hazards model using a penalized spline for the FEV 1 slope, males and females combined. The spline
crossed above zero for the log HR at –59 ml/yr for (a) COPD morbidity, at –74 ml/yr for (b) COPD or CHD mortality, and at –77 ml/yr
for (c) all-cause mortality. Models adjusted for baseline age, height-adjusted baseline lung function (FEV1/height2), and height. Tick
marks on the x axis represent the frequency of the various FEV1 slope values.
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7Appendix B: Sensitivity Analyses for Study 2
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Examination 1
1976–78

Examination 2
1982–83

13,825 Subjects

8,033 Subjects

Objective 2
subcohort:
6,659 Subjects

Objective 3
subcohort:
1,766 Subjects

Examination 3
1991–94
9,515 Subjects

Examination 4
2001–03

End of Follow-up
2006
2009

5,329 Subjects

879 COPD Morbidity

Spirometry and ascertainment
of asthma, chronic bronchitis,
and shortness of breath

1,191 COPD or CHD Mortality
4,203 All-cause Mortality

Spirometry and ascertainment
of chronic bronchitis and
shortness of breath

107 COPD Morbidity
336 All-cause Mortality

Figure B.1 Sample sizes and morbidity and mortality follow-up by study objective. Above the timeline are the numbers of subjects who participated in spirometry testing by Copenhagen City Heart Study
examination. Below the timeline are the numbers of subjects who met the criteria for each objective and the numbers of health outcomes that occurred during the morbidity and mortality follow-up periods for
each objective. Note that the follow-up periods are represented as dashed lines and that follow-up for COPD or CHD mortality ended in 2006.
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Table B.1 Characteristics of the subcohorts for the Cox proportional hazards model analysis
Males

Females

Never smokers

Subcohort 2: Subjects present for examinations one and two*
Subjects with baseline age ≤ 45 (or ≤ 50) (n, %)†
Baseline age (mean, SD)
Subjects with baseline age > 45 (or > 50) (n, %)†
Baseline age (mean, SD)
Slope FEV1, ml/yr (median, SD)§

798

12.0

37.5
2,102

6.1
31.6

57.8
–76

7.6
87

953
37.8
2,806
57.4
–57

14.3
5.9
42.1
7.2
64

495
39.4
760
60.6

7.4
7.3
11.4
6.5

–58; –40‡

94; 67‡

60.4

462

26.2

9.4

44.8

10.0

Subcohort 3: Subjects present for all examinations*
Subjects (n, %)†
Baseline age (mean, SD)

700

39.6

44.0

9.9

1,066
45.3

Slope FEV1, ml/yr (median):
Examination one to two

–59

–57

–56; –57‡

Examination three to four

–55

–40

–48; –39‡

*Spirometry tests were 4 to 7 years apart from examination one to two and 7 to 12 years apart from examination three to four.
†A total of 6,659 subjects were present for examinations one and two and 1,766 for all examinations.
‡Males; females.
§Overall median and standard deviation values, not age-stratified.
FEV1, forced expiratory volume in one second; ml/yr, milliliters/year; SD, standard deviation.
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Table B.2 Cox proportional hazards models for longitudinal lung function (Examination one to two)*, †
Males
Females

COPD Morbidity

Never Smokers

Baseline Age
≤ 45 Years

Baseline Age
> 45 Years

Baseline Age
≤ 45 Years

Baseline Age
> 45 Years

(n=796; COPD=82)

(n=2,705; COPD=295)

(n=950; COPD=92)

(n=2,788; COPD=410)

HR

95% CI

HR

95% CI

95% CI

95% CI

(n=879; COPD=47)
HR

95% CI

1.16

(0.63–2.16)

2.05

(1.39–3.02)

1.97

(1.05–3.68)

2.23

(1.64–3.04)

0.43

(0.05–3.65)

1.18

(0.44–3.13)

Q3 FEV1 slope

2.14

(1.18–3.88)

2.72

(1.88–3.93)

2.51

(1.29–4.87)

2.90

(2.11–3.97)

1.33

(0.20–8.79)

2.22

(0.83–5.94)

Q4 FEV1 slope

1.67

(0.82–3.44)

5.21

(3.53–7.68)

5.53

(2.92–10.47)

4.89

(3.53–6.78)

0.00

(0.00–0.00)

2.52

(0.88–7.18)

Asthma

1.03

(0.24–4.48)

1.50

(0.98–2.28)

1.14

(0.47–2.78)

1.05

(0.70–1.56)

29.25

(4.48–191.20)

2.41

(0.60–9.75)

Chronic bronchitis

1.75

(1.00–3.05)

1.82

(1.38–2.40)

4.15

(2.52–6.82)

2.05

(1.60–2.63)

21.97

(3.01–160.34)

2.25

(0.82–6.18)

Shortness of breath

1.46

(0.61–3.50)

1.89

(1.37–2.62)

1.17

(0.63–2.19)

2.18

(1.66–2.86)

0.74

(0.06–9.69)

1.64

(0.59–4.52)

COPD or CHD Mortality

(n=798; Deaths=50)

Q1 FEV1 slope

1.00

Q2 FEV1 slope

1.27

(0.57–2.83)

1.14

(0.89–1.46)

1.97

(0.66–5.84)

1.64

(1.25–2.14)

2.37

(0.23–24.25)

1.18

(0.68–2.03)

Q3 FEV1 slope

1.97

(0.89–4.37)

1.41

(1.11–1.79)

1.88

(0.57–6.25)

1.93

(1.47–2.53)

4.46

(0.42–47.14)

1.31

(0.74–2.31)

Q4 FEV1 slope

2.25

(0.95–5.35)

1.93

(1.50–2.49)

5.64

(1.88–16.85)

3.17

(2.39–4.19)

1.42

(0.08–26.81)

1.41

(0.76–2.63)

Asthma

1.55

(0.46–5.22)

0.79

(0.54–1.18)

1.25

(0.30–5.15)

0.73

(0.49–1.09)

2.94

(0.26–32.66)

0.93

(0.26–3.36)

Chronic bronchitis

1.06

(0.51–2.23)

1.32

(1.07–1.62)

1.80

(0.69–4.68)

1.50

(1.18–1.90)

2.16

(0.21–21.77)

1.54

(0.81–2.95)

Shortness of breath

4.25

(1.92–9.41)

2.11

(1.66–2.69)

1.40

(0.48–4.11)

1.91

(1.49–2.45)

2.55

(0.28–23.41)

1.05

(0.52–2.14)

All-cause Mortality

(n=798; Deaths=251)
HR

HR

(n=953; Deaths=29)

95% CI

1.00

95% CI

(n=2,102; Deaths=1,752)
HR

HR

95% CI

1.00

95% CI

1.00

1.00

95% CI

1.00

(n=2,102; Deaths=592)

1.00

(n=373; COPD=4)
HR

Q2 FEV1 slope

95% CI

1.00

HR

Baseline Age
> 50 Years

Q1 FEV1 slope

HR

1.00

HR

Baseline Age
≤ 50 Years

(n=2,806; Deaths=520)
HR

95% CI

1.00

(n=953; Deaths=204)
HR

95% CI

1.00

1.00

(n=373; Deaths=1)
HR

95% CI

1.00

(n=2,806; Deaths=1,996)
HR

95% CI

1.00

HR

95% CI

1.00

(n=373; Deaths=47)
HR

(n=882; Deaths=127)

95% CI

1.00

(n=882; Deaths=580)
HR

95% CI

Q1 FEV1 slope

1.00

Q2 FEV1 slope

1.00

(0.70–1.44)

1.23

(1.07–1.41)

1.40

(0.95–2.07)

1.32

(1.16–1.51)

0.69

(0.35–1.37)

1.22

(0.94–1.58)

Q3 FEV1 slope

1.64

(1.15–2.33)

1.22

(1.06–1.40)

1.24

(0.81–1.88)

1.42

(1.24–1.62)

1.22

(0.63–2.38)

1.26

(0.95–1.65)

Q4 FEV1 slope

2.13

(1.47–3.08)

1.67

(1.44–1.94)

1.89

(1.23–2.89)

1.92

(1.66–2.20)

1.20

(0.59–2.45)

1.51

(1.13–2.02)

Asthma

0.55

(0.20–1.50)

0.80

(0.62–1.04)

0.92

(0.44–1.91)

1.03

(0.81–1.32)

1.16

(0.27–5.00)

1.11

(0.62–1.99)

Chronic bronchitis

1.28

(0.91–1.80)

1.19

(1.05–1.35)

1.11

(0.70–1.75)

1.36

(1.19–1.56)

1.32

(0.40–4.36)

1.48

(1.08–2.02)

Shortness of breath

1.87

(1.16–3.00)

1.57

(1.34–1.85)

1.32

(0.84–2.08)

1.28

(1.11–1.49)

1.66

(0.64–4.29)

1.06

(0.76–1.48)

3

*Adjusted for baseline age, height-adjusted baseline lung function (FEV1/height ), and height.
†Asthma and respiratory symptoms ascertained at examination two and represented as dichotomous variables in all models.
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Table B.3 Cox proportional hazards models for patterns in lung function decline and respiratory symptoms (Examinations one to two and three to four)*, †
COPD Morbidity

Males

Females

Never smokers

(n = 675; COPD = 45)

(n = 1,022; COPD = 62)

(n =453; COPD =8)§

HR

95% CI

HR

95% CI

Slope FEV1
1) Normal decline over both periods

1.00

2) Excessive decline over period one only

3.26

(0.86–12.33)

3.13

3) Excessive decline over period two only

5.62

(1.61–19.63)

2.77

(1.12–6.82)

10.49

(3.00–36.70)

4.06

(1.53–10.74)

4) Excessive decline over both periods

1.00
(1.17–8.35)

Chronic bronchitis
1) Absent in both periods

1.00

2) Present in period one only

0.00

(0.00–0.00)

1.00
2.61

(0.74–9.15)

3) Present in period two only

1.86

(0.91–3.83)

1.74

(0.91–3.32)

4) Present in both periods

3.24

(1.33–7.89)

3.28

(1.52–7.09)

Shortness of breath
1) Absent in both periods

1.00

2) Present in period one only‡

0.00

(0.00–0.00)

2.07

(0.47–9.14)

3) Present in period two only

3.75

(1.86–7.55)

6.35

(3.50–11.53)

5.91

(1.38–25.39)

4.34

(1.72–10.93)

4) Present in both periods
All-cause Mortality

1.00

(n = 700; Deaths = 152)
HR

95% CI

(n = 1,066; Deaths = 184)
HR

95% CI

(n = 462; Deaths =59)
HR

95% CI

Slope FEV1
1) Normal decline over both periods

1.00

2) Excessive decline over period one only

1.24

(0.73–2.11)

1.00
1.23

(0.78–1.96)

1.00
2.04

(0.87–4.77)

3) Excessive decline over period two only

1.91

(1.16–3.12)

1.43

(0.91–2.23)

1.41

(0.58–3.42)

4) Excessive decline over both periods

2.17

(1.30–3.62)

1.64

(1.03–2.62)

1.62

(0.66–3.94)

Chronic bronchitis
1) Absent in both periods

1.00

2) Present in period one only

0.68

(0.29–1.57)

1.00
0.90

(0.33–2.48)

1.00
1.78

(0.22–14.05)

3) Present in period two only

1.09

(0.71–1.69)

1.36

(0.89–2.07)

2.08

(0.99–4.37)

4) Present in both periods

0.84

(0.44–1.63)

1.86

(1.09–3.17)

0.72

(0.10–5.23)

Shortness of breath
1) Absent in both periods

1.00

2) Present in period one only

0.68

(0.09–4.88)

1.00
1.12

(0.35–3.56)

3.40

(0.43–26.76)

3) Present in period two only

1.97

(1.21–3.21)

1.71

(1.11–2.63)

1.19

(0.42–3.40)

4) Present in both periods

1.91

(0.66–5.51)

1.64

(0.78–3.47)

0.54

(0.07–4.44)

*Adjusted for baseline age, height-adjusted baseline lung function (FEV1/height3), and height.
†Respiratory symptoms ascertained at examination two and represented as dichotomous variables in all models.
‡Note that no COPD morbidity events occurred for males in pattern 2 for shortness of breath.
§Sensitivity analysis was not possible due to too few cases overall after excluding the adjusted 1981 FEV1 values.
FEV1, forced expiratory volume in one second; ml/yr, milliliters/year; SD, standard deviation.
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Examination 1
1976–78

Examination 2
1982–83

13,825 Subjects

8,033 Subjects

End of Follow-up
2006
2009

928 COPD Morbidity

Study cohort: Spirometry at examinations
6,777 Subjects

1,242 COPD or CHD Mortality

one and two

4,305 All-cause Mortality

Figure C.1 Sample size and morbidity and mortality follow-up. Above the timeline are the numbers of subjects who participated in spirometry testing by Copenhagen
City Heart Study examination. Below the timeline is the number of subjects who participated in spirometry testing at examinat ions one and two and the numbers of
health outcomes that occurred during the morbidity and mortality follow-up periods. Note that the follow-up periods are represented as dashed lines and that followup for COPD or CHD mortality ended in 2006.
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Study Cohort

Baseline FEV 1
in Comparison
to Predicted

Category by
Quartile of
FEV1 Slope
1. Quartile 1
(n = 248)
reference
2. Quartile 2
(n = 402)

FEV1b ≥
Predicted
3. Quartile 3
(n = 543)

4. Quartile 4
(n = 837)
Spirometry at
examinations
one and two
(n = 6,777)

5. Quartile 1
(n = 889)

FEV1b <
Predicted
and ≥ LLN

9. FEV1b < LLN
(n = 1,265)

6. Quartile 2
(n = 980)

7. Quartile 3
(n = 906)

8. Quartile 4
(n = 707)

Figure C.2 Nine lung function categories based on baseline FEV1 values in comparison to predicted values and quartiles of FEV1
slope. European reference equations were used to calculate the predicted FEV 1 values.111 FEV1b, baseline forced expiratory volume
in one second; LLN, lower limit of normal.
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Table C.1 Characteristics of the subcohorts for the Cox proportional hazards model analysis
Males

Females

Never Smokers

Subjects present for examinations one and two*
Subjects (n, %)†
Baseline age (mean, SD)

2,953

43.6

3,824

56.4

1,261

18.6

52.3

11.6

52.4

11.0

52.3

12.4

Subjects with baseline age ≤ 45 (mean, SD)

37.5

6.1

37.7

5.9

39.4

7.3

Subjects with baseline age > 45 (mean, SD)

57.9

7.6

57.4

7.2

60.6

6.5

COPD morbidity

16.8

8.6

19.4

7.8

20.9

7.4

COPD or CHD mortality

16.5

7.8

19.0

6.8

19.9

6.4

All-cause mortality

17.3

8.6

20.0

7.6

21.2

7.3

Years of follow-up (mean, SD)

FEV1b, l (mean, SD)
FEV1b, % predicted (mean, SD)

3.09

18.4

2.25
91.7

0.56

3.48; 2.32‡

0.86; 0.57‡
16.5; 18.3‡

18.2

95.4; 96.5‡

FEV1b ≥ predicted (n, %)

790

26.8

1,240

32.4

526

Q1 Slope FEV1 (n, %)

106

13.4

142

11.5

41

7.8

Q2 Slope FEV1 (n, %)

151

19.1

251

20.2

126

24.0

Q3 Slope FEV1 (n, %)

208

26.3

335

27.0

140

26.6

Q4 Slope FEV1 (n, %)

88.8

0.83

41.7

325

41.1

512

41.3

219

41.6

1,521

51.5

1,961

51.3

600

47.6

Q1 Slope FEV1 (n, %)

373

24.5

516

26.3

126

21.0

Q2 Slope FEV1 (n, %)

423

27.8

557

28.4

226

37.7

Q3 Slope FEV1 (n, %)

393

25.8

513

26.2

157

26.2

Q4 Slope FEV1 (n, %)

332

21.8

375

19.1

91

15.2

642

21.7

623

16.3

135

10.7

–68

87

–50

64

FEV1b < predicted and ≥ LLN (n, %)

FEV1b < LLN (n, %)
Slope FEV1, ml/yr (mean, SD)
25th percentile
Median
th

75 percentile
Never smokers (n, %)§

–58; –46‡

–127

–95

–116; –95‡

–76

–57

–58; –40‡

–19

–19

299

10.1

Former smokers (n, %)§

777

Current smokers (n, %)§

1,868

0; 0‡

962

25.2

26.3

793

20.7

63.3

2,038

53.2

299; 962‡

*Spirometry tests were 4 to 7 years apart from examination one to two with a mean follow-up of 5 years.
†A total of 6,777 subjects were present for examinations one and two.
‡Males; females.
§Ascertained at examination two.
FEV1b, baseline forced expiratory volume in one second; l, liters; LLN, lower limit of normal; ml/yr, milliliters/year; SD, standard deviation.
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95; 67‡

23.7; 76.3‡

C.3a. COPD Morbidity

C.3b. COPD or CHD Mortality

C.3c All-cause Mortality

Figure C.3 Cox proportional hazards model results for overall (a) morbidity, (b) COPD or CHD mortality, and (c) all-cause mortality
risks by lung function category. Models adjusted for baseline age and height. FEV1b, baseline forced expiratory volume in one
second; LLN, lower limit of normal; pred., predicted value.
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Table C.2 Population attributable risks (PAR) for morbidity and mortality in the
overall study cohort*
HR
95% CI
PAR (%)
COPD Morbidity

(n = 6,721; COPD = 928)

Categories 1–8

1.00

Category 9

4.11

Categories 1–7

1.00

Categories 8 and 9
COPD or CHD Mortality

4.45
1.00

Category 9

2.64

Categories 1–7

1.00

All-cause Mortality

36.2

(3.90–5.08)

49.7

(n = 6,777; Deaths = 1,242)

Categories 1–8

Categories 8 and 9

(3.59–4.71)

2.67

(2.33–2.99)

23.4

(2.38–3.00)

32.7

(n = 6,777; Deaths = 4,305)

Categories 1–8

1.00

Category 9

1.80

Categories 1–7

1.00

Categories 8 and 9

1.86

*Cox models adjusted for baseline age and height.
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(1.68–1.94)

13.0

(1.74–1.98)

20.0

25%

20%

15%

10%

5%

0%
FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < LLN
and Q1 slope and Q2 slope and Q3 slope and Q4 slope and ≥ LLN and and ≥ LLN and and ≥ LLN and and ≥ LLN and
Q1 slope
Q2 slope
Q3 slope
Q4 slope

Figure C.4 Overall prevalence rates of self-reported respiratory symptoms (chronic bronchitis = solid line; shortness of breath =
dashed line) at examination two by lung function category. The Spearman’s rho rank correlations were –0.97 (p < 0.0001) between
the lung function categories and chronic bronchitis and –0.95 (p < 0.0001) between the lung function categories and shortness of
breath. FEV1b, baseline forced expiratory volume in one second; LLN, lower limit of normal; pred., predicted value.
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Table C.3 Cox proportional hazards models for morbidity and mortality risks by lung function category and subcohort*
Males
HR

Females
95% CI

HR

95% CI

Never Smokers
HR

95% CI

COPD Morbidity

(n=2,919; COPD=401)

(n= 3,802; COPD=527)

FEV1b ≥ pred. and Q1 slope

1.00

1.00

FEV1b ≥ pred. and Q2 slope

1.00

(0.32–3.16)

1.08

(0.32–3.67)

0.10

(0.01–1.01)

FEV1b ≥ pred. and Q3 slope

1.62

(0.60–4.38)

1.75

(0.58–5.26)

0.11

(0.01–1.01)

FEV1b ≥ pred. and Q4 slope

1.52

(0.57–4.02)

3.49

(1.25–9.74)

0.33

(0.08–1.36)

FEV1b < pred. and ≥ LLN and Q1 slope

1.35

(0.51–3.57)

4.95

(1.79–13.67)

0.60

(0.14–2.51)

FEV1b < pred. and ≥ LLN and Q2 slope

1.93

(0.75–4.93)

6.25

(2.28–17.09)

0.72

(0.20–2.62)

FEV1b < pred. and ≥ LLN and Q3 slope

3.70

(1.48–9.25)

6.61

(2.41–18.12)

1.21

(0.34–4.32)

FEV1b < pred. and ≥ LLN and Q4 slope

6.90

(2.77–17.15)

14.24

(5.22–38.85)

1.42

(0.37–5.52)

10.36

(4.25–25.26)

20.81

(7.71–56.19)

1.41

(0.38–5.23)

FEV1b < LLN

1.00

COPD or CHD Mortality

(n=2,953; Deaths=669)

(n= 3,824; Deaths=573)

FEV1b ≥ pred. and Q1 slope

1.00

1.00

FEV1b ≥ pred. and Q2 slope

0.95

(0.46–1.94)

2.19

(0.89–5.37)

FEV1b ≥ pred. and Q3 slope

0.98

(0.50–1.90)

2.36

(0.98–5.66)

FEV1b ≥ pred. and Q4 slope

1.27

(0.68–2.36)

3.75

(1.62–8.66)

FEV1b < pred. and ≥ LLN and Q1 slope

1.32

(0.71–2.44)

4.06

(1.75–9.39)

FEV1b < pred. and ≥ LLN and Q2 slope

1.34

(0.73–2.47)

4.48

(1.95–10.28)

FEV1b < pred. and ≥ LLN and Q3 slope

1.68

(0.92–3.07)

5.08

(2.21–11.69)

FEV1b < pred. and ≥ LLN and Q4 slope

2.81

(1.54–5.12)

8.77

(3.82–20.18)

3.24

(1.81–5.81)

14.80

(6.53–33.56)

FEV1b < LLN
All-cause Mortality

(n=2,953; Deaths=2,054)

(n= 1,258; COPD=52)

(n=3,824; Deaths=2,251)
1.00

(n=1,261; Deaths=129)†

(n= 1,261; Deaths=632)

FEV1b ≥ pred. and Q1 slope

1.00

FEV1b ≥ pred. and Q2 slope

0.98

(0.68–1.41)

1.27

(0.94–1.72)

1.00
1.39

(0.78–2.45)

FEV1b ≥ pred. and Q3 slope

0.97

(0.69–1.36)

1.36

(1.02–1.82)

1.57

(0.89–2.75)

FEV1b ≥ pred. and Q4 slope

1.21

(0.88–1.66)

1.57

(1.19–2.07)

1.49

(0.87–2.56)

FEV1b < pred. and ≥ LLN and Q1 slope

1.29

(0.95–1.76)

1.63

(1.24–2.16)

1.51

(0.85–2.66)

FEV1b < pred. and ≥ LLN and Q2 slope

1.48

(1.09–2.01)

1.89

(1.44–2.48)

1.74

(1.01–2.99)

FEV1b < pred. and ≥ LLN and Q3 slope

1.53

(1.12–2.07)

1.84

(1.40–2.42)

1.60

(0.92–2.78)

FEV1b < pred. and ≥ LLN and Q4 slope

2.31

(1.70–3.14)

2.72

(2.06–3.59)

2.50

(1.42–4.41)

FEV1b < LLN

2.46

(1.83–3.31)

3.28

(2.51–4.30)

2.28

(1.31–3.99)

*Adjusted for baseline age and height.
†Sensitivity analysis was not possible due to a lack of cases in the reference category after excluding the adjusted 1981 FEV1 values.
FEV1b, baseline forced expiratory volume in one second; LLN, lower limit of normal; pred., predicted value.
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Table C.4 Cox proportional hazards models for morbidity and mortality risks by lung function category and baseline age*
Baseline Age ≤ 45
HR
COPD Morbidity

95% CI

(n= 1,768; COPD=178)

Baseline Age > 45
HR

95% CI

(n= 4,953; COPD=750)

FEV1b ≥ pred. and Q1 slope

1.00

FEV1b ≥ pred. and Q2 slope

0.96

(0.21–4.28)

1.08

(0.39–2.97)

FEV1b ≥ pred. and Q3 slope

1.92

(0.52–7.09)

1.69

(0.69–4.14)

FEV1b ≥ pred. and Q4 slope

1.64

(0.46–5.87)

2.69

(1.15–6.28)

FEV1b < pred. and ≥ LLN and Q1 slope

2.54

(0.76–8.49)

3.19

(1.37–7.40)

FEV1b < pred. and ≥ LLN and Q2 slope

2.66

(0.79–8.92)

4.38

(1.92–10.03)

FEV1b < pred. and ≥ LLN and Q3 slope

3.23

(0.97–10.82)

5.75

(2.52–13.10)

FEV1b < pred. and ≥ LLN and Q4 slope

6.39

(1.94–21.05)

11.30

(4.97–25.67)

FEV1b < LLN

7.83

(2.45–24.99)

17.70

(7.88–39.79)

COPD or CHD Mortality

1.00

(n=1,773; Deaths=81)

(n= 5,004; Deaths=1,161)

FEV1b ≥ pred. and Q1 slope

1.00

FEV1b ≥ pred. and Q2 slope

0.24

(0.03–2.31)

1.62

(0.90–2.92)

FEV1b ≥ pred. and Q3 slope

1.04

(0.25–4.35)

1.62

(0.92–2.86)

FEV1b ≥ pred. and Q4 slope

0.61

(0.14–2.71)

2.32

(1.36–3.98)

FEV1b < pred. and ≥ LLN and Q1 slope

1.04

(0.28–3.84)

2.56

(1.50–4.38)

FEV1b < pred. and ≥ LLN and Q2 slope

1.22

(0.34–4.44)

2.63

(1.54–4.47)

FEV1b < pred. and ≥ LLN and Q3 slope

1.09

(0.29–4.12)

3.15

(1.85–5.34)

FEV1b < pred. and ≥ LLN and Q4 slope

2.37

(0.67–8.43)

5.06

(2.98–8.60)

FEV1b < LLN

3.33

(1.01–10.93)

6.92

(4.12–11.62)

All-cause Mortality

1.00

(n= 1,773; Deaths=466)

(n= 5,004; Deaths=3,839)

FEV1b ≥ pred. and Q1 slope

1.00

1.00

FEV1b ≥ pred. and Q2 slope

0.83

(0.40–1.69)

1.20

(0.94–1.53)

FEV1b ≥ pred. and Q3 slope

1.59

(0.85–2.96)

1.17

(0.93–1.48)

FEV1b ≥ pred. and Q4 slope

1.43

(0.78–2.61)

1.38

(1.11–1.73)

FEV1b < pred. and ≥ LLN and Q1 slope

1.61

(0.90–2.87)

1.48

(1.19–1.85)

FEV1b < pred. and ≥ LLN and Q2 slope

1.69

(0.95–3.02)

1.72

(1.38–2.13)

FEV1b < pred. and ≥ LLN and Q3 slope

1.58

(0.87–2.85)

1.70

(1.37–2.12)

FEV1b < pred. and ≥ LLN and Q4 slope

2.67

(1.49–4.77)

2.49

(2.00–3.11)

FEV1b < LLN

2.98

(1.71–5.19)

2.85

(2.30–3.52)

*Adjusted for baseline age and height.
FEV1b, baseline forced expiratory volume in one second; LLN, lower limit of normal; pred., predicted value.
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10%

0%
FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b ≥ Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < Pred. FEV1b < LLN
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Figure C.5 Cumulative incidence by lung function category, for three subcohorts (■ = males; ● = females; ▲ = never smokers) and
three outcomes (COPD morbidity = solid line; COPD or CHD mortality = dashed line; all-cause mortality = dash dot line). FEV1b,
baseline forced expiratory volume in one second; LLN, lower limit of normal; pred., predicted value.
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